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Abstract 
INVESTIGATING THE IMPACT OF INTRAGENIC DNA METHYLATION ON GENE 
EXPRESSION, AND THE CLINICAL IMPLICATIONS ON TUMOR CELLS AND 
ASSOCIATED STROMA 
 
Michael Hefner McGuire, B.S. 
Advisory Professor: Anil Sood, M.D. 
 
Investigations into the function of non-promoter DNA methylation have yielded 
new insights into epigenetic regulation of gene expression. Previous studies have 
highlighted the importance of distinguishing between DNA methylation in discrete 
functional regions; however, integrated non-promoter DNA methylation and gene 
expression analyses across a wide number of tumor types and corresponding normal 
tissues have not been performed. Through integrated analysis of gene expression 
and DNA methylation profiles, we uncovered an enrichment of DNA methylation sites 
within the gene body and 3’UTR in which DNA methylation is strongly positively 
correlated with gene expression. We examined 32 tumor types and identified 57 
tumor suppressors and oncogenes out of 224 genes containing a correlation of > 0.5 
between gene body methylation and gene expression in at least 1 tumor type. The 
lymphocyte-specific gene CARD11 exhibits robust association between gene body 
methylation and expression across 19 of 32 tumor types examined. It is significantly 
overexpressed in KIRC and LUAD, and has a z-score of 4 in KIRC, meaning that high 
expression of CARD11 in this tumor type was associated with lower patient overall 
survival. Contrary to its canonical function in lymphocyte NF-kB activation, CARD11 
activates the mTOR pathway in KIRC and LUAD, resulting in suppressed autophagy, 
vii 
 
and demethylation of a CpG island within the gene body of CARD11 decreases gene 
expression. In addition to methylation of the open reading frame portion of a gene, 
other regions of site-specific DNA methylation along the gene body remain to be 
explored. Upon segregating the gene body into discrete functional units (5’UTR, 1st 
exon, 3’UTR), it was noted that the 3’UTR contained an enrichment of probes 
positively correlated between DNA methylation and gene expression. In 5 of 10 tumor 
types examined, DNA methylation of the 3’UTR is associated with patient survival in 
a significant number of genes. Filtering for genes in which 3’UTR DNA methylation, 
relative to gene body DNA methylation, is more strongly correlated with gene 
expression yields a list of 156 genes, enriched for functions involving T cell activation. 
Activating T cells ex vivo caused the immune checkpoint gene HAVCR2, but not other 
genes examined, to show a substantial increase in 3’UTR DNA methylation, but not 
adjacent exonic/intronic, or promoter DNA methylation, upon upregulation of gene 
expression. Furthermore, this increase in HAVCR2 gene expression can be 
abrogated by treatment with demethylating agents. These findings implicate the 
3’UTR as a functionally relevant DNA methylation site, particularly regarding T cell 
activity. Additionally, they reveal a novel mechanism by which HAVCR2 is 
upregulated in T cells, providing a new molecular target for immune checkpoint 
blockade.  
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Chapter 1: Introduction 
 
Section 1.1: The Molecular and Cellular Biology of DNA Methylation 
  
DNA methylation is a modification that can be added directly to the DNA of a 
cell. It consists of a methyl group (a carbon with three hydrogens attached) that is 
most commonly added to a CpG dinucleotide (Fig1.), but can also be added to CpT, 
CpA, or CpC dinucleotides, depending on the cell type (17), and can also appear at 
position 6 of adenines (18). DNA methylation can be deposited or removed through 
passive methylation, active (de novo) methylation, or active (de novo) demethylation 
(19) 
 
 Passive DNA methylation occurs when identical patterns of DNA methylation 
are maintained from parent somatic cell to daughter somatic cell during cell division 
(20), primarily through the Dnmt1 enzyme. Dnmt1 has robust enzymatic activity 
toward hemi-methylated DNA (21), which occurs after DNA replication, when the 
parent strand contains methylated CpGs, and the newly synthesized daughter strand 
lacks DNA methylation (22) (Fig2.). The Dnmt1 enzyme adds a methyl group to the 
daughter strand at the same location as where the methylation exists on the parent 
strand (23), allowing for passing down of methylation patterns during DNA synthesis 
and cell division. However, cells require the ability to alter their DNA methylation 
patterns for a variety of reasons, including as they differentiate, or enter into different 
states of activation (24). Therefore, cells must de novo methylate or demethylate 
specific loci. De novo methylation can be carried out by the aforementioned Dnmt1 
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enzyme, but is more commonly governed by the activity of Dnmt3a and Dnmt3b (25), 
as well as the co-factor Dnmt3L (26).  Together, these enzymes can alter DNA 
methylation patterns based on intracellular and extracellular stimuli, allowing for 
flexibility in cellular regulation of gene expression according to the context.  
3 
 
 
 
 
Figure 1: (Top): DNA methylation occurs by enzymatic 
activity, which adds a methyl group to position 5 of the 
cytosine carbon ring. Figure taken with permission from 
<http://www.ks.uiuc.edu/Research/methylation/> 
Figure 2: (Bottom): DNA demethylation can occur 
passively, when DNA methylation enzymes are inhibited, as 
DNA replicates; DNA methylation can also be an active 
process dependent upon enzymatic activity. Figure taken 
with permission from <Wu, S. and Zhang, Y. Active DNA 
demethylation: many roads lead to Rome. Nature Reviews 
Molecular Cell Biology 2010(14)> 
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Conversely, dynamic changes to the epigenome also necessitates the 
capacity of the cell to de novo demethylate specific loci based on varying stimuli. This 
demethylation is most comprehensively understood to occur by the TET enzymes 
(27). As an example, TET1 induces the conversion of 5-methylcytosine (5-mC) into 
5-hydroxymethylcytosine (28). This conversion can result in indirect demethylation 
after DNA replication due to Dnmt1 not recognizing 5-hmC as methylated CpG, 
thereby leading to an unmethylated daughter stand (19). On the other hand, 5-hmC 
can be deaminated by AID or APOBEC cytidine deaminases, resulting in 5-
hydroxymethyluridine (5-hmU) which then is recognized by the Base Excision Repair 
pathway, removing the 5-hmU and replacing it with an unmethylated cytosine (29) 
(Fig3.). Through the Dnmt and TET enzymes, cells can both maintain and modulate 
their methylation profiles. 
 
 
 
 
 
Figure 3: TET enzymes catalyze the conversion of 5-mC to 5-hmC, 5-fC, and 5-
caC, which is then recognized by the base excision pathway that replaces the 
modified cytosine with an unmethylated cytosine. Taken with permission from 
<https://www.epigentek.com/catalog/dna-demethylation.php> 
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Differences in DNA methylation are a major contributor to the remarkable 
plasticity amongst cells that share identical genomes by providing a means of 
activating or silencing genes whose expression impacts the developmental or 
activation state of specific cell types (30). This plasticity is primarily due to the 
capacity of DNA methylation to affect the ability of site-specific proteins to bind to a 
target sequence (31) (Fig4.). 
 
Figure 4:  (a) Methylation of the promoter can attract methylation-
specific binding proteins which prevent transcription factors from 
activating transcription. (b) Methylation of the enhancer can occlude 
this region from binding the necessary co-factors to initiate 
transcription. (c) Conversely, methylation of the enhancer can provide 
a binding site for transcription-activating factors. Taken with 
permission from :<Spruijt, C. and Vermeulen, M. DNA methylation: old 
dog, new tricks? Nature Structural & Molecular Biology 2014(8)> 
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Proteins such as transcriptional repressors or activators may have increased 
or decreased binding affinity to a target sequence when a methyl group is present at 
this location (32). Furthermore, DNA methylation can affect the binding of adaptor  
proteins that can recruit co-factors responsible for modifying histones (33).  
The modification of histones has profound effects on the structure and 
accessibility of DNA (34), thereby influencing manifold cellular processes (35) (Fig5.
). 
 
Figure 5: Histones are composed of 4 subunits, with tails that can be 
modified through methylation and acetylation at various locations, which 
impacts the structure of the histones and therefore access to regions of 
DNA. Taken with permission from <Li, S. et al. Host-virus interactions: 
from the perspectives of epigenetics. Rev Med Virol 2014(6)> 
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  Mammalian development is heavily dependent on DNA methylation, as this 
process consists of a single cell giving rise to daughter cells with a large variety of 
different phenotypes (30). After fertilization, embryos undergo genome-wide 
demethylation, with levels of methylation remaining low until implantation, in which 
pluripotent cells begin to differentiate (36). A striking example of global changes to 
DNA methylation occur during hematopoiesis, where multi-potent progenitor cells 
give rise to numerous cell types that acquire more rigid specificity of function (37) (Fig
6.). 
 
 
Figure 6: The different methylation states of each cell type and each tissue grants 
plasticity in morphology and function. These states evolve over time during cell 
differentiation. Taken with permission from <Suarez-Alvarez, B. et al. DNA 
methylation: a promising landscape for immune system-related diseases. Trends in 
Genetics 2012 (10)> 
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Given the broad range of regulatory power, fully elucidating the function and 
regulation of DNA methylation is integral to a complete understanding of cellular 
biology. 
Subsection 1.1.1: Promoter Methylation 
DNA methylation is widespread throughout the genome. However, methylation 
at the gene promoter region is the most comprehensively understood. Regulatory 
promoter DNA methylation typically occurs within CpG islands, which are regions of 
DNA enriched for CpG dinucleotides (38, 39). This results in powerful repression of 
transcription, primarily by recruiting repressor proteins or chromatin modifiers that 
enhance the binding of DNA to histones, resulting in formation of inaccessible regions 
called heterochromatin (40, 41) (Fig7.). 
 
Figure 7: Methylation of the DNA can prompt the binding of chromatin-modifying 
enzymes that remove histone acetylation/add histone methylation, resulting in 
formation of heterochromatin, and preventing access to the DNA. Taken with 
permission from <Raabe, FJ. and Spengler, D. Epigenetic risk factors in PTSD and 
depression. Frontiers Psychiatry 2013(15)> 
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This allows for an “off switch” for gene expression within each individual cell 
by altering their accessibility. Methylated promoters typically contain the H3K27me3 
histone modification, causing an adoption of tightly associated DNA/histone 
interactions, which are tightly wound together, sequestering the genes away from 
transcriptional activators (42). Therefore, when the CpG island of a gene promoter is 
methylated, this gene can be considered “turned off”; however, if the promoter is 
unmethylated, this does not guarantee that the gene will be expressed, but only that 
it can be readily expressed if the necessary transcription factors, co-factors, and 
transcriptional complexes are present (43). 
 
1.1.2: Enhancer Methylation 
 Enhancers, as their name implies, enhance the transcription of a downstream 
gene by serving as a binding site for transcription factors and co-factors that can 
activate or boost gene expression (44) (Fig8.). 
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Figure 8: The enhancer is located upstream of the promoter, and during 
transcriptional activation, is bound by activators which interact with transcription 
factors and RNA polymerase through bending of the DNA. Taken with permission from 
<http://www.mun.ca/biology/desmid/brian/BIOL2060/BIOL2060-23/CB23.html> 
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In a similar fashion to promoter sequences, the methylation of enhancer 
sequences can modulate the ability of said factors to bind and influence gene 
expression (45, 46), and DNA methylation of enhancers is inversely correlated with 
expression of enhancer-regulated genes (47). Also like promoter methylation, 
enhancer methylation alters the chromatin structure by promoting changes to the 
chromatin architecture via recruitment of histone modifiers. Methylated enhancers are 
highly associated with H3K27me3, a repressive marker, and are inversely correlated 
with H3K27ac, which promotes an open chromatin state, and access to DNA (48) 
(Fig9.).  
 
 
Figure 9: Like promoters, enhancer DNA and histones can be modified, 
typically by methylation or acetylation. These modifications influence the 
activation state of the genes they regulate by impacting the ability of critical 
factors and co-factors necessary for transcriptional activation. Taken with 
permission from <Atlasi, Y. and Stunnenberg, H. The interplay of epigenetic 
marks during stem cell differentiation and development. Nature Reviews 
Genetics 2017(12)> 
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Conversely, hydroxymethylated CpGs in the enhancer region (a product of TET 
enzymatic activity on methylated CpGs as discussed above), are associated with 
H3K27ac and H3K4me1, two markers of highly active gene expression (49, 50). 
Taken together, DNA methylation at enhancers can impart powerful repression on 
downstream genes in a manner similar to promoter methylation. 
 
Subsection 1.1.3: Intergenic Methylation 
 Intergenic DNA is any region of DNA that is not a part of a gene or a regulatory 
element, and makes up approximately 75%-90% of the genome (51). While these 
regions do not code for proteins, they can code for non-coding RNAs, many of which 
are essential for regulating cellular processes (52). Therefore, understanding the 
intergenic methylation landscape holds key insights into cell biology. Indeed, the 
regulation by intergenic methylation of important non-coding RNAs such as Xist(53) 
and Air (54) have been thoroughly demonstrated. New non-coding RNAs transcribed 
from the intergenic region are discovered each year, and with these discoveries 
comes a growing importance for ascertaining the effects of intergenic methylation.  
 Approximately 45% (55) of intergenic DNA consists of the remnants of 
genomic parasites such as retroviruses, transposons, and retrotransposons (56) (Fig
10.).  
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These transposable elements are oftentimes detrimental to the normal function of the 
cell, and their replication and transcription are actively opposed by cellular defense 
mechanisms (57, 58). The primary mechanism for suppressing transposable 
elements is DNA methylation, and the cell’s effort to inactivate these parasites is 
estimated to account for 35% of all the DNA methylation found in the genome (59).  
 
Figure 10 : Multiple types of transposons exist, and are classified by how they 
replicate themselves. Some transposons are converted to RNA and reverse 
transcribed into DNA, whereas others do not go through an RNA intermediate. 
Taken with permission from <Bonchev, G. and Parisod, C. Transposable elements 
and microevolutionary changes in natural populations. Molecular Ecology 
Resources 2013(7)> 
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Repression of transposable elements by DNA methylation typically occurs by 
methylating the promoter region of the transposable element, thereby silencing its 
expression (60). Loss of DNA methylation enzymes and co-factors result in 
substantially increased transcription of these elements(58), which can cause 
catastrophic cellular consequences, such as meiotic recombination in mitotic cells 
(61). 
 DNA methylation can also take place at insulators, which serve to diminish 
transcriptional activity by disrupting the interaction between enhancers and 
transcriptional sites through looping of the DNA; additionally, insulators isolate 
heterochromatic regions, preventing them from spreading to euchromatic areas (62). 
The most well-studied cause for how methylation impacts these sites is through 
excluding CTCF binding(63). CTCF is instrumental in forming functionally isolated 
segments of DNA through chromatin looping(64). Binding of DNA by CTCF is 
methylation sensitive (65), and methylation at CTCF binding regions is highly variable 
in different tissues (66) (Fig11.).  
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Figure 11: CTCF induces isolated regions of DNA through chromatin looping. CTCF 
binding to its target sequence is methylation sensitive. If CTCF is bound to DNA in 
between an enhancer and its corresponding promoter, it can inhibit the transcriptional 
activation effects of the enhancer. Therefore, these binding sites are called “insulators”, 
because they insulate segments of DNA. Taken with permission from <van Montlfoort, 
AP. Et al. Assisted reproduction treatment and epigenetic inheritance. Hum. Reprod. 
Update 2012(16)> 
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Intergenic methylation is therefore highly important for normal cellular function, and 
unraveling currently unknown functions has the potential to reveal novel insights into 
gene regulation and genomic structural assembly. 
 
Subsection 1.1.4: Gene Body Methylation 
Gene body methylation, also called intragenic methylation, is the term used to 
describe methylation on any part of the gene that is transcribed into mRNA. This 
includes exons and introns, as well as the 5’ and 3’UTR, and accounts for 40% of all 
methylated CpGs in the mammalian genome (67). Unlike promoter methylation, gene 
body methylation has a more complicated set of functions that can either increase or 
decrease gene expression, both directly and indirectly. Some of the first 
investigations involving this type of modification were conducted on the active X 
chromosome (68). The active X chromosome is differentially methylated from its 
inactive counterpart, and is characterized by methylation in the gene body of certain 
highly expressed genes (69). A large-scale study of cell line-specific genome-wide 
methylation levels observed high gene body methylation in highly expressed genes 
that was generalizable to the entire genome (70). Further analysis of gene body 
methylation uncovered a robust association with H3K36me3, a histone marker of 
actively transcribed genes (71) (Fig12.). 
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Figure 12: DNA methylation is low in the promoter region and enriched within the gene 
body of actively transcribed genes. Gene body methylation is strongly associated with 
H3K36me3. Taken with permission from <Moreselli, M. et al. In vivo targeting of de novo 
DNA methylation by histone modifications in yeast and mouse. Elife 2015(2). 
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 While there is evidence that DNA methylation may be downstream of 
activated transcription and H3K36me3 deposition (72), gene body methylation has 
been shown to be upstream of gene expression, and blocking re-methylation of a 
gene can abrogate its expression (73).  
 Much remains to be understood about the mechanisms by which gene body 
methylation conveys its effects. Indeed, multiple mechanisms have been uncovered, 
depending on the specific location of the methylation. Like promoter methylation, 
gene body methylation can suppress expression, but not of the gene itself; rather, it 
serves to prevent spurious transcription of downstream promoters. An analysis of 
differentially methylated regions within the gene body showed these locations to have 
similar architecture as promoters (74). By suppressing intragenic transcription 
initiation, methylation of the gene body results in greater transcription from the 
canonical transcription initiation site, leading to greater expression. This phenomenon 
is primarily mediated by Dnmt3b, and is dependent on H3K36me3 deposition by the 
SetD2 enzyme (75). Generally speaking, exons contain higher levels of methylation 
relative to introns (76, 77). Additionally, the intron/exon junction is enriched for 
methylation, pointing to a role in determining the boundaries between these regions 
of genes (78).  Gene body methylation has also been shown to directly modulate 
mRNA splicing by recruiting the methylation-sensitive protein MeCP2 to an exon that 
is typically spliced out of the mRNA product (79). This causes a slowing of the RNA 
polymerase, which results in inclusion of the MeCP2-bound exon. Additionally, 
methylation of a weak exon in the CD45 gene prevents CTCF binding, which results 
in a splicing out of the exon when methylated (80) (Fig13.). 
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Figure 13: Methylation of a specific exon within the CD45 
gene prevents CTCF from binding. Binding of CTCF to this 
exon slows the RNA polymerase, which facilitates inclusion of 
the exon into the mRNA transcript. Therefore, methylation of 
the exon induces its exclusion, which demonstrates that DNA 
methylation can influence RNA splicing. Taken with permission 
from <Shukla, S. et al. CTCF-promoted RNA polymerase II 
pausing links DNA methylation to splicing. Nature 2011(4). 
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 In certain contexts, dense gene body methylation can diminish transcriptional output, 
mainly by inducing chromatin structures that close the gene off to RNA polymerase 
binding(81). Given these diverse and often contradictory functions, the impact of gene 
body methylation on normal cellular processes and disease remains a topic requiring 
further exploration. 
 
Section 1.2: DNA Methylation in Disease 
Given the numerous purposes of DNA methylation as described above, 
aberrant changes to DNA methylation can be both a cause and a consequence of 
disease (82). From the very beginning of a new life, DNA methylation is essential; 
embryonic differentiation requires proper DNA methylation, and loss of DNA 
methylation results in embryonic lethality (83).  Mutations to methylation enzymes 
have been linked to diseases such as Immunodeficiency, Centromeric Instability and 
Facial Anomalies syndrome, of which approximately 70% of patients contain a 
DNMT3B mutation (84). Furthermore, mutations in DNMT1 lead to a variety of 
neurodegenerative conditions, including Hereditary Sensory and Autonomic 
neuropathy (85, 86). One group of diseases indirectly linked to DNA methylation are 
those caused by expansion of repetitive sequences (82). For example, Fragile X 
Syndrome is characterized by numerous repeats of CGG trinucleotides in the FMR1 
gene, which serves as a target for hypermethylation, and consequently reduces 
transcription of this gene (87) (Fig14.). Conversely, hypomethylation due to tandem 
repeats as seen in Facioscapulohumeral Muscular Dystrophy can also be deleterious 
(88).   
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Figure 14:  In Fragile X syndrome, tandem 
repeats of the CGG trinucleotide sequence can 
result in hypermethylation of this region, which 
silences transcription of the gene, and produces 
deleterious effects. Taken with permission from 
<http://modencode.sciencemag.org/drosophila/aut
ism/> 
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 A major source of methylation-related disease is improper imprinting(82). 
Because imprinting allows for allele-specific gene expression, improper expression 
of both alleles, or abnormal paternal/maternal expression can disrupt cellular 
processes. One specific example is that of Prader-Willi Syndrome (PWS), in which a 
piece of chromosome 15 loses normal imprinting patterns. The consequence is lack 
of expression of paternal alleles in this region(89), which together cause mental 
impairment and behavioral issues. Another disease, Angelman Syndrome (AS), also 
arises from changes to imprinting on chromosome 15 in approximately 5% of cases, 
and has been isolated due to a single gene, UBE3A. This ubiquitin ligase is 
specifically expressed from the maternal allele in the brain, and loss of imprinting 
leads to neurological defects (90). Numerous other disorders result from similar 
changes to normal imprinting (91).  
 
Subsection 1.2.2: DNA Methylation in Cancer 
DNA methylation patterns experience global changes within cancer cells (92). 
These changes can be summarized into two groups: regions of hypomethylation and 
regions of hypermethylation (93). In general, cancer cell genomes are 
hypomethylated (93), with intergenic regions containing the most drastic differences 
(94), as well as centromeric and pericentrimeric regions (95).  
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Figure 15: Cancer DNA methylation is characterized by hypermethylated promoters 
of tumor suppressors, hypomethylated promoters of oncogenes, global decrease in 
DNA methylation, and resulting genomic instability. Taken with permission from 
<Phillips, T. The role of methylation in gene expression. Nature Education 2008(5) 
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Perturbed methylation of these areas contributes significantly to the cancer 
hallmark of genomic instability (96). Hypomethylation produces genomic instability 
through multiple mechanisms, such as increased transcription of transposable 
elements (97), destabilization of centromeres (98, 99), and errors in chromosome 
segregation during mitosis (100). Genomic instability through changes in methylation 
can lead to higher rates of mutation, hastening tumorigenesis and/or worsening tumor 
progression (101). Hypomethylation can also directly influence gene expression, 
oftentimes by promoter demethylation and consequent overexpression of 
oncogenes(Fig15.). This is frequently observed in imprinted genes (94). As a specific 
example, certain growth-regulatory genes such as IGF2 are only expressed from the 
maternal or paternal allele (102) by allele-specific methylation; when normal 
imprinting is disrupted, both alleles are switched on, causing dysregulated cell 
growth. This phenomenon has been observed across multiple tumor types, including 
colorectal cancer (103), prostate cancer (104), and others (105, 106). Furthermore, 
loss of imprinting in IGF2 serves as a marker of colorectal cancer risk (107). Promoter 
demethylation of oncogenes is also frequently observed, and can worsen outcomes. 
ELMO3, a gene that promotes NSCLC migration and metastasis, contains less 
promoter methylation and higher expression in metastases than in primary tumors or 
untransformed cells (108). Numerous other oncogenes display a similar phenomenon 
(109). As our knowledge of site-specific methylation across the genome continues to 
grow, so too the list of oncogenic processes influenced by hypomethylation will grow 
as well. 
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 While the vast majority of the cancer genome experiences hypomethylation, 
hypermethylation of specific regions substantially impacts the formation and 
progression of nearly every type of cancer (110). The function of tumor suppressor 
genes such as TP53 are frequently inactivated through mutation (111), but mutation 
is a random process, whereas DNA methylation allows cancers to eliminate tumor 
suppressors in an controlled manner. Since the p53 protein is the “guardian of the 
genome” (112), it comes as no surprise that the TP53 is frequently methylated in 
cancer cells relative to normal cells (113-115). Other genes essential for genomic 
integrity, such as the mismatch repair gene MLH1 are observed to be switched off by 
promoter methylation in cancer, compromising mismatch repair, and massively 
increasing mutation rates (116). In addition to impacting genomic stability, aberrant 
tumor suppressor methylation can immensely increase cell proliferation and growth 
by targeting cell cycle regulators. For example, the CDKN2B gene is a negative 
regulator of cell cycle, and is frequently methylated in ovarian cancer, leading to 
unrestrained tumor growth (117). Moreover, aberrant epigenetic modification has 
been implicated in immune evasion through downregulation of antigen presentation 
molecules, tumor-specific antigens, apoptosis-inducing receptors, and receptors 
employed by NK cells to kill tumor cells (118).  
 In summary, cancer DNA methylation experiences global changes, both 
hypomethylation and hypermethylation, that serve as a driver both for tumorigenesis 
and for tumor progression. Therefore, developing clinical strategies to modulate these 
changes in the epigenome is a promising avenue to developing new clinical tools to 
treat cancer. 
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Subsection 1.2.2: Clinical Strategies for Targeting DNA Methylation 
 Given the systemic changes in cancer DNA methylation as discussed above, 
gaining the ability to normalize or disrupt the epigenetic network established in cancer 
holds therapeutic potential. Therefore, drugs that modulate DNA methylation have 
become increasingly studied, both at the pre-clinical and clinical levels (119). Two 
broad categories of demethylating drugs exist: non-nucleoside analogs and 
nucleoside analogs (120). Non-nucleoside analogs typically convey their effects 
through direct actions to DNMT enzymes (119). For example, procanimide works as 
a competitive inhibitor for DNMT1 binding, preventing DNMT1 from methylating DNA 
(121). While these therapies produce lower toxicity relative to nucleoside analogs, 
they also achieve lower levels of demethylation (122).  Nucleoside analogs are those 
drugs that are incorporated into nucleic acids (123). Two forms of this type of 
methylation inhibition have been employed in the clinic: azacytidine and 5’-deoxy-
azacytidine (119). These work by incorporating themselves into actively replicating 
DNA, then trap DNMT enzymes and induce their degradation by the proteasome  
(124) (Fig16.). 
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Figure 16: Azacytidine works by binding to 
the DNMT enzymes, which lead to their 
degradation by the proteasome pathway. 
Upon DNA replication, lack of DNMT enzymes 
result in passive DNA demethylation. Taken 
with permission from 
<http://www.vidaza.net/mds/about-
vidaza/moa/> 
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Therefore, these inhibitors require DNA replication to convey their effects, 
making them well-suited for cancer, which replicates its DNA more rapidly than 
normal cells (125). These drugs are currently being used in cancer patients, with 
blood-borne diseases being the most susceptible (126, 127). Currently, these two 
types of drugs are approved for use in AML, CMML, and MDS (128), with clinical trials 
also being conducted in solid tumors such as melanoma and renal cell carcinoma 
(120). Interestingly, recent reports have shown demethylating agents to boost T cell 
killing of tumor cells (129), and to have a synergistic effect with immune checkpoint 
inhibitors (130-132). However, not all patients respond to either demethylating agents 
alone, or in combination; therefore, a greater understanding of which patients should 
receive this therapy, and the specific mechanism of how this therapy conveys its 
effects, is needed. 
 
Section 1.3: Non-coding RNAs 
 The central dogma of molecular biology is that DNA-based genes are 
transcribed into messenger RNAs, which are then translated into proteins that exert 
specific functions (133). However, a more comprehensive understanding of genomics 
has broadened our conception of what constitutes a gene, and what composes the 
final product of a gene (52). While protein coding genes make up only 2% of the 
genome, upwards of 70% of the genome is transcribed into RNA (134). RNAs that do 
not code for a protein have been discovered many years ago, particularly those 
involved in the ribosomes (135) and transfer RNAs (136). Due to technologies such 
as RNA-seq, our knowledge of RNAs that are transcribed but never code for a protein 
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has expanded exponentially (137). Non-coding RNAs have now been implicated in a 
wide range of cellular processes, and constitute an essential means of regulation(52). 
Numerous types of non-coding RNAs exist, from the aforementioned transfer and 
ribosomal RNAs, to piRNAs, snoRNAs, and snRNAs (138) (Fig17.); this discussion 
will focus on long non-coding RNAs (lncRNAs).  
Furthermore, RNAs that arise from the opposite strand of genes, called natural 
antisense transcripts, will also be discussed separately, although many fall under the 
categories of lncRNAs and microRNAs (139). 
 
 
Figure 17: Non-coding RNAs can fall into several 
groups, including microRNAs, small RNAs, and medium 
to long RNAs that are involved in a wide variety of 
cellular processes. Taken with permission from 
<https://noncodingrnaexplorer.wordpress.com/non-
coding-rnas/> 
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Subsection 1.3.1: Long non-coding RNAs 
  Long non-coding RNAs are any RNAs that contain > 200 nucleotides (140). 
They can be transcribed from introns, from intergenic RNA, or can overlap with exons 
(141). Like messenger RNA, lncRNAs can contain exons and introns (142). Because 
of the inherent flexibility of RNA, lncRNAs can fold into structures that can function 
as an enzyme (143), or that can bind DNA, proteins, or other RNAs, and function as 
scaffolds (144). 
 
 
 
 
Figure 18: The flexible nature of RNA allows for lncRNAs to function as 
enzymes, as scaffolds, or as sponges for other RNAs.  Taken with permission 
from <Malik, B. and Feng, F. Long noncoding RNAs in prostate cancer: 
overview and clinical implications. Asian Journal of Andrology 2016(9)>  
31 
 
 
Given this plasticity, lncRNAs are involved in processes ranging from transcriptional 
regulation, to chromatin modification, to post-transcriptional regulation (143) (Fig18.
). Arguably, the most well-studied lncRNA is that of XIST, which induces the silencing 
of the X chromosome in cells that contain two X chromosomes (145). 
 
  While the mechanism of XIST is complicated, one of the most essential 
features is its recruitment of PRC2, a chromatin modifier that methylates H3K27, 
causing formation of heterochromatin and gene silencing (146). In this case, one 
domain of the lncRNA is capable of recognizing specific regions of DNA, while 
another domain can bind to PRC2, resulting in localization of PRC2 to the region to 
be silenced, a common mechanism of lncRNA function. As mentioned, lncRNAs can 
also bind mRNAs; this aspect will be explained in the natural antisense transcripts 
section. 
 
Subsection 1.3.2: Natural Antisense Transcripts 
Natural antisense transcripts (NAT) are any RNA transcripts that are 
transcribed from the opposite strand of a gene (147). Previously written off as 
transcriptional noise (148, 149), new technologies have implicated these fascinating 
RNA molecules as more than a byproduct (150-153). NAT can regulate gene 
expression both in cis and in trans through a variety of mechanisms, including 
transcriptional interference (154), modulating DNA methylation (76), imprinting (155), 
influencing histone modification (156), and impacting sense mRNA stability (157) (Fig
19.). 
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Figure 19: Natural Antisense transcripts can have a wide range of both in cis and 
in trans functions, such as blocking sense transcription through RNA polymerase 
collision, modulating RNA splicing, promotion or inhibition of RNA stability, and 
induction of chromatin modification. Taken with permission from <Lapidot, M. and 
Pilpel, Y. Genome-wide natural antisense transcription: coupling its regulation to its 
different regulatory mechanisms. EMBO 2006(11) 
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Due to the overlapping sites of transcription between sense and antisense 
strands, active transcription of the antisense can result in decreased expression of 
the sense mRNA (154). This is primarily due to the sheer size of the transcriptional 
complex physically occluding transcriptional initiation, as well as collision of the two 
transcriptional complexes as they transcribe toward one another (158, 159). The 
antisense transcript of HBA2 extends into the promoter CpG island, and knockout of 
the antisense RNA prevents the methylation of this promoter, thereby resulting in 
increased expression of HBA2 (160).  The IGF2R gene is well known to be imprinted, 
and this imprinting depends on expression of a NAT (161). The paternal copy of 
IGF2R contains an unmethylated CpG island in an intron, which regulates expression 
of the NAT AIR, which represses expression of IGF2R by recruiting transcriptional 
repressors in cis to this locus (162). The NAT ANRIL is capable of binding to 
chromobox 7 of the Polycomb Repressor Complex, and can localize this histone 
modifying enzyme to discrete regions of the INK4/ARF gene complex, inducing 
H3K27 methylation, which silences expression of these genes through 
heterochromatin formation (163).  
 Considering the diverse functions of NAT, mutation or aberrant expression of 
these RNAs can play a role in diseases, including cancer (164-166). For example the 
aforementioned targets of ANRIL, INK4/ARF, are tumor suppressor genes(167). 
ANRIL expression is altered in many cancers (168-170), and through a variety 
mechanisms both in cis and in trans, can disrupt genomic stability (171) and normal 
cellular proliferation (171). Another example is that of the ZEB2 NAT, which impacts 
cancer metastasis (172). The ZEB2 NAT promotes retention of the ZEB2 mRNA 
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5’UTR, which is critical for efficient translation (172) (Fig20.).  Therefore, determining 
the function of NATs, especially those who are antisense to oncogenes or tumor 
suppressors, are essential for a complete understanding of tumorigenesis and tumor 
progression. Furthermore, they provide novel therapeutic targets. 
 
 
Figure 20: The NAT of Zeb2 is critical for retention of the Zeb2 5’UTR in 
the mRNA transcript. Retention of the 5’UTR promotes efficient translation, 
which thereby increases Zeb2 protein. This process is important for 
mediating EMT. Taken with permission from <Serviss, J. et al. An emerging 
role for long non-coding RNAs in cancer metastasis. Front. Genet. 
2014(13)> 
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Section 1.4: Immunology 
 Human immunology is an extraordinarily complex system composed of scores 
of specific cell types that carry out specific roles in defending the body from invaders, 
both from outside the body and from within (173). Immune cells begin with a common 
progenitor cell, and differentiate into a spectacular array of cell types, a process 
known as hematopoiesis (174). This is governed through a complex series of cell-
specific changes to gene expression, which is accomplished primarily through 
modulating the epigenetic profile (175). Investigating changes to the immune 
epigenome has major implications for autoimmune disease, treatment of lymphoma, 
immunotherapy, vaccine generation, and a host of other topics. Therefore, gaining a 
comprehensive understanding of how the epigenome is controlled, and the functional 
implications of these modifications, is essential for developing new drugs and 
advancing medicine.  
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The immune system can be broken down into two major components: innate and 
adaptive immunity (176) (Fig21.).  
 
 
Figure 21: The immune system can be broken down into two major components: 
the innate immune system is activated rapidly upon foreign invasion, and consists 
of cells such as granulocytes, macrophages, and dendritic cells that both eliminate 
the invader, and prime the immune system for long-term combat. The adaptive 
immune system is triggered by the innate immune system, and can work over the 
span of days to weeks. The adaptive immune system specifically hones in on 
targets after being primed by antigen from the innate immune system. Taken with 
permission from <https://cias.rit.edu/faculty-staff/101/faculty/336> 
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The innate immune system serves as the first line of defense against 
pathogens, activating within the span of minutes (177). Innate immunity is a general 
phenomenon that does not determine its targets based on specific epitopes; rather, 
it can rid regions of pathogens or toxins through non-specific recognition of foreign 
bodies (178). 
 
Common bacterial epitopes such as lipopolysaccharides and common viral 
molecules like double-stranded RNA serve as triggers that induce immune cells to 
unleash a torrent of cytokines and other factors that recruit more immune cells to the 
site of interest (179). The most numerous cell types include neutrophils, 
macrophages, and dendritic cells, which perform the actions listed above, and serve 
as a link to the adaptive immune system (180). 
 Dendritic cells and macrophages, along with other cell types, are able to 
activate the adaptive immune response by presenting molecules obtained from 
foreign bodies on their surfaces (181). The two most prominent cell types of adaptive 
immunity are that of B cell and T cells (181). B cells are responsible for secreting 
antibodies that can bind with exquisite precision to specific antigens on a systemic 
scale (182). When the B cell receptor comes in contact with an antigen presented by 
dendritic cells, macrophages, etc., that matches, it will trigger the production of large 
quantities of secreted antibodies, which upon binding to their target, can render the 
target non-functional, as well as induce destruction by other cell types in the area 
(182). Antibodies work with such efficacy and specificity, that dozens of monoclonal 
antibodies toward various targets in both cancer and other diseases, have proven as 
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beneficial in the clinic (183). For example, a monoclonal antibody against the B cell 
receptor CD20, called rituximab, has been approved for multiple types of blood 
cancers (184). However, despite massive successes, monoclonal antibodies have 
major limitations, such as the ability only to bind surface molecules, and the capacity 
of cancer to gain mutations that invalidate the antibody targeting (185). Therefore, 
the greatest immunological response also requires activation of T cells, which are 
able to target intracellular or extracellular proteins. 
 
Subsection 1.4.1: T cells 
 T cells, similar to B cells, are activated upon stimulation by antigen presented 
by antigen-presenting cells that binds to their T cell receptor (186). This triggers clonal 
expansion of the activated T cell, primarily through intracellular signaling from the T 
cell receptor to downstream targets such as NF-kB (187) and mTOR (188). T cells 
come in two overarching types: CD4 and CD8, which carry out different functions in 
mounting an immune response (189). CD4 cells are known as “T helper cells”, which 
support other immune cells through the secretion of cytokines such as IFNγ, IL-2, and 
IL-4 (190). Some CD4 T cells serve as negative regulators of immune response as a 
means of reigning in immune activation after a threat has been dealt with. These are 
known as regulatory T cells, and are a major mechanism by which cancer evades the 
immune system (191). CD8 T cells, also known as cytotoxic T cells, directly interact 
with and destroy any cells that express antigen that binds with their T cell receptor 
(192) (Fig22.). Therefore, CD8 T cells offer great potential in seeking out and killing 
tumor cells at an individual cell basis. Understanding how CD8 T cell killing is 
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mediated and regulated is therefore of utmost importance in treating diseases, 
whether it be cancer, autoimmune disease, or infection. 
 
Figure 22: T cells are activated by recognizing antigen that is presented on the MHC by 
antigen-presenting cells such as macrophages and dendritic cells. Upon stimulation, T cells 
undergo clonal expansion, and can specifically seek out and kill cells that express the 
antigen that their T cell receptor recognizes. Taken with permission from 
<http://bit.ly/2GXvLDR> 
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Subsection 1.4.2: Cancer Immunology 
The immune response to cancer becomes gradually compromised by specific 
mechanisms employed by the tumor to evade immune recognition (193). This is 
accomplished through direct and indirect interaction with immune cells (193). 
However, for every collection of cancer cells that become a full-fledged tumor, many 
potential cancer cells are recognized and removed by the immune system, whereas 
a compromised immune system creates a more favorable environment for tumor 
development and growth (194). Due to mutation, cancer cells produce proteins that 
can be discerned from “self”, allowing for an immune response (195). How the tumor 
is able to circumvent this system is the topic of the following discussion.  
Cancer has two primary strategies for evading the immune system: the first is 
to prevent cancer-detecting and –killing immune cells from entering the tumor 
microenvironment, and the second is to alter, suppress, or invalidate the function of 
the immune cells that are present in the microenvironment (196). One example of 
how tumors can alter cellular phenotype is that of macrophages, which undergo a 
phenomenon called polarization that causes them to adopt an anti-tumor (M1) or pro-
tumor (M2) cellular state (197). Tumors push macrophages to the M2 phenotype by 
secreting factors such as CCL2, CSF1, and IL-4, as well as by producing hypoxic 
conditions that induce these changes (198). M2 macrophages then assist the tumor 
in immunosuppression, growth, angiogenesis, and metastasis (199). Tumors 
suppress dendritic cells by blocking upstream dendritic cell differentiation, and inhibit 
antigen presentation through secretion of factors such as IL-10 and VEGF (200). The 
most potent anti-tumor role of dendritic cells is the priming of T cells, which as 
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previously mentioned, can identify and kill tumor cells on an individual cell basis. 
Therefore, a frequent strategy of tumor cells is to prevent T cells from infiltrating into 
the microenvironment (201). The central mechanism is by downregulating the surface 
proteins on endothelium that cause T cells to identify the site of interest (202), and by 
depositing stromal components that block T cell infiltration (203). This is a highly 
effective strategy, as low T cell infiltration is a robust predictor of tumor growth and 
spread (204).  Additionally, tumor cells will actively recruit T regulatory cells and 
myeloid-derived suppressor cells, which are immunosuppressive cells that inhibit 
cytotoxic T cells (205). If T cells are able to navigate to the cancer microenvironment, 
tumor cells are able to exploit immune pathways that rein in the immune response in 
order to evade being killed. 
  
Subsection 1.4.3: Immune Checkpoint 
 Just like every cellular process, the immune system must have a mechanism 
for activation, and a mechanism for repression once the threat has been dealt with. 
In the case of cytotoxic T cells, this mechanism comes in the form of the immune 
checkpoint pathways. Over the past two decades, components of immune checkpoint 
pathways have been and continue to be uncovered (206). To date, the two most 
clinically important pathways are the CTLA-4 and the PD-1/PD-L1 pathways. The 
CTLA-4 pathway was first discovered by Dr. James Allison as a negative regulator of 
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T cell priming and activation when they are being stimulated by antigen-presenting 
cells (207). (Fig23.). 
 
Figure 23: During T cell activation that occurs when a T cell engages antigen 
specific to its receptor via antigen-presenting cells, co-activation of T cell 
CD28 by B7 is also required. CTLA-4 can bind to B7 and prevent the 
necessary co-activation signals required for T cell activation. 
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Based on this understanding, it was hypothesized that blocking CTLA-4 could 
induce greater T cell activity in cancer patients, leading to increased tumor cell killing 
by cytotoxic T cells. This hypothesis proved correct, providing stark, sustained 
survival benefits and stable or eliminated disease in a fraction of patients, with the 
most efficacious tumor type being advanced stage melanoma, a disease that had few 
treatment options (208). The second immune checkpoint that has served as a clinical 
target is the PD-1/PD-L1 pathway. While CTLA-4 functions between antigen-
presenting cells and T cells, PD-1/PD-L1 works at the interaction between a T cell 
and its potential target (209). When PD-L1 is expressed by the target cell, it functions 
as an “off switch” for the T cell, preventing it from killing the target. PD-L1 is 
overexpressed in numerous cancers, which has allowed for PD-1/PD-L1 inhibitors to 
achieve remarkable success in treating a diverse set of tumor types (210) (Fig24.). 
 
 
Figure 24: PD-1/PD-L1 binding between tumor and T 
cell nullifies activation of the T cell receptor. Blocking 
this interaction with an antibody can reactivate T cells. 
For the National Cancer Institute © (3-21-18) Terese 
Winslow LLC, U.S. Govt. has certain rights 
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However, some patients respond extremely well, while others do not respond 
at all, necessitating a great need for biomarkers (210). Furthermore, a large variety 
of drugs, including CTLA-4, are now being used in combination with PD-1/PD-L1 
inhibitors to boost efficacy (211). One promising discovery in this regard has been 
that of the TIM-3 protein, which is a powerful regulator of T cell exhaustion, and has 
been implicated in resistance to PD-1/PD-L1 therapy (212). Therefore, greater 
understanding the mechanisms that govern expression and function of these immune 
checkpoints is essential for rational discovery of biomarkers, as well as efficacious 
combinations that fully harness the potential of immune checkpoint blockade. 
 
Section 1.5: Autophagy 
 Autophagy is a cellular process that grants cells the ability to “eat themselves” 
in certain contexts by degrading and recycling components of the cytoplasm such as 
organelles (213). There are multiple contexts in which this process is important for 
normal cell function and cell survival. For example, autophagy is employed to 
sequester and degrade protein aggregates that can accumulate in cells (214). Loss 
of autophagy in this context results in cell death, and in line with this function, 
autophagy has been linked to Alzheimer’s disease (215). Conversely, autophagy is 
typically activated in low-nutrient conditions. This allows for the cell to persist without 
external nutrients by recycling macromolecules in non-essential organelles (216) (Fig
25.). 
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Figure 25: Autophagy is a process by which intracellular components can be 
degraded and recycled. These components are engulfed by a lipid membrane 
that forms the autophagosome. This then fuses with the lysosome, which 
contains degradative properties that can break down the cellular components. 
These macromolecules are then used based on the cell’s need.  
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The central regulator of autophagy activation is mTOR (217). This signaling 
node is activated in the context of plentiful nutrients, as it serves to drive cell growth 
and proliferation. Therefore, when nutrients are low, the mTOR pathway is 
inactivated, which can then trigger induction of autophagy (218). However, mTOR 
pathway inactivation is not the only step necessary to activate this process. Atg1, a 
serine/threonine kinase, must be activated, which then phosphorylates downstream 
mediators of autophagy such as Atg13 and Atg17. Furthermore, Beclin-1 must be 
dissociated from its negative regulator for autophagy to proceed. This illustrates the 
tight regulation of this process (217).   
The process of autophagy can be roughly divided into two stages: early stage 
and late stage (219). The early stage consists of the initial steps, until formation of 
the autophagosome. When autophagy is induced, the cytoplasmic target is engulfed 
in an autophagosome, which initially consists of a double membrane containing 
proteins such as ATG5 and ATG12. In the late stage, the autophagosome fuses with 
the lysosome, creating the autophagolysosome. The lysosome contains low pH and 
numerous degradative enzymes that facilitate the breakdown of components 
contained within the autophagolysosome. The degraded molecules are then exported 
to the cytoplasm by a process still not well-understood (220). 
Given the nature of autophagy, as well as the functions outlined above, too 
much or too little can be detrimental to the cell, and can eventually lead to cell death 
(221). Like apoptosis, autophagy can function as a cellular mechanism to induce 
death in certain contexts, including in developmental programming or stress-inducing 
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extrinsic factors (222). Therefore, the ability to modulate autophagy in cancer cells 
offers a promising avenue for induced cell death. 
 
Subsection 1.5.1: Autophagy and cancer 
 Autophagy plays a complex role in various types of cancer, and depending on 
the context, can function as either oncogenic or tumor suppressive (223). For 
example, since autophagy is involved in mitigating oxidative stress, reduced 
autophagy can increase this condition in tumor cells, which may promote 
tumorigenesis through greater genomic instability (224). This is borne out both in the 
lab and in the clinical setting. The critical autophagy gene BECN1 is frequently found 
deleted in prostate cancer (225). Mice heterozygous for this gene have been shown 
to spontaneously develop lung and liver cancer (226). Conversely, autophagy can be 
highly beneficial to tumor cells, particularly when considering the high-stress 
intracellular and extracellular environment that results from cancer metabolism (227). 
One clear example of this is the metabolically overtaxed cancer cells with RAS 
mutations. These tumor cells have been shown to contain high levels of autophagy, 
which has been hypothesized to be a coping mechanism that allows cells to survive 
in an otherwise hostile situation (228). Indeed, genetic ablation of autophagy genes 
in this context results in diminished tumor burden, primarily through activation of p53 
as a result of intracellular stress signals (229). Whether autophagy is acting as tumor 
suppressive or oncogenic, these data make it clear that tight regulation of this process 
is essential for optimal cancer growth and progression; because of this fine balance, 
tipping the scale in one direction or another could be catastrophic for tumor cells. A 
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greater understanding of autophagy in each tumor type, how it is regulated, and the 
functional consequences of perturbing this process, are essential for developing 
novel therapeutic avenues for targeting cancer. 
 
Section 1.6: Bioinformatics and TCGA 
 A decade and a half ago, the Human Genome Project successfully sequenced 
the entire human genome; today, the human genome can be rapidly sequenced for 
less than $5,000 (230). Moreover, new technologies such as RNA-seq, genome-wide 
methylation assays, and RPPA has necessitated scientists skilled at large-scale data 
analysis. In the era of personalized medicine, the disciplines of bioinformatics and 
biostatistics are becoming ever-more important. The emergence of this skillset has 
been particularly valuable for cancer, which consists of numerous mutations and 
network alterations that require a birds-eye view to piece together (231). This had led 
to the many important insights, such as mutational frequency among tumor types and 
tumors within a single type, among many others (232). Therefore, collaboration 
between molecular biologists, physicians, and bioinformaticians is a powerful 
combination that will facilitate discoveries that would not have been accomplished by 
each individual discipline. 
 
 The Cancer Genome Atlas (TCGA) is a publicly funded and worldwide 
collaborative endeavor that performs multiple forms of molecular profiling of patient 
normal and tumor tissue across over 30 different tumor types (233), including survival 
data. The molecular profiling includes RNA-seq, genome-wide methylation arrays, 
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DNA sequencing, RPPA, and more (233). These datasets are publicly available, and 
have served as the basis for numerous publications. Here, we have harnessed these 
datasets to investigate relationships between site-specific DNA methylation and gene 
expression across at least 10 tumor types. This has revealed two key discoveries: 
3’UTR methylation as important in regulation of TIM-3, and the connection between 
CARD11 gene body methylation, gene expression, and kidney renal cell cancer 
progression. 
Overall Summary 
 With the advent of large-scale epigenomic profiling, novel discoveries into 
how the epigenome changes during tumorigenesis and tumor progression are being 
uncovered. However, little is known about how these changes impact cancer 
pathogenesis, particularly in regard to regions outside of the promoter. Therefore, a 
comprehensive investigation into how epigenetic changes such as DNA methylation 
play a role in these processes is warranted, both within the tumor cells themselves, 
as well as within the stromal compartment. The following study seeks to add to the 
knowledge of how DNA methylation functions in regard to gene expression, and 
what the consequences of changes to these functionally relevant sites of DNA 
methylation are in relation to cancer pathogenesis. 
 
Section 2: Materials and Methods 
Cell Culture 
The UOK111 renal cell carcinoma cells were a kind gift from Dr. Eric Jonasch. These 
cells were grown in DMEM (Clontech) +10% FBS +1% PenStrep, and were split upon 
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reaching 80% confluency. The H1975 lung adenocarcinoma cells were a kind gift 
from Dr. John Heymach. These were grown using RPMI (Clontech) +10% FBS +.1% 
gentamycin. These cells were split upon reaching 80% confluency. Each cell line was 
validated using STR testing, and were low passage. 
 
Western Blotting 
Cells were spun down at 1,500xRPM for 5 minutes, then the spin was repeated after 
washing with PBS. Cell pellets were then re-suspended in RIPA buffer, and quantified 
using the BCA assay (Thermo Scientific Pierce BCA Protein Assay Kit). Equal 
amounts of protein were run on an SDS-PAGE gel (8%-12%), then transferred to a 
nitrocellulose membrane, and incubated in 5% milk (in TBS-T) for one hour, then 
incubated in primary antibody overnight. Blots were then washed with TBS-T for 3x20 
minutes, then incubated in secondary antibody (GE Healthcare, 1:2000) for one hour. 
ECL was then added to the blots for 3 minutes, then exposed to a film for 
quantification of protein. The following antibodies were used: anti-CARD11 (Cell 
Signaling Technology, 1:1000), anti-phosphoP70S6K (Cell Signaling Technology, 
1:1000), anti-P70S6K (Cell Signaling Technology, 1:3000), anti-GAPDH (1:5000), 
anti-LC3B (Cell Signaling Technology, 1:1000). 
 
siRNA Transfection 
Cells to be transfected were plated in 6-well plates at 50% confluency the day of 
transfection. For each well, 1.3µg of siRNA was added to 50µL of serum-free media, 
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and in a separate tube, 4µL of FuGene HD Transfection Reagent (Promega) was 
incubated in 50µL of serum-free media for 5 minutes. The siRNA/media mixture was 
then added dropwise to the transfection reagent mixture, mixed, then incubated for 
15 minutes. Cells to be transfected were washed once with PBS, then 900µL serum-
free media per well was added. 100µL of siRNA mixture was added dropwise to each 
well, which was then mixed, and placed in the incubator for 4-6 hours. Serum-free 
media was replaced with complete media. Reverse transfections were performed 2-
3 days after forward transfections. 4µg of siRNA per well was added to 500µL serum-
free media. In a separate tube, 8µL of RNAiMAX (Thermo Fiscer) was added to 500µL 
of serum-free media, and incubated for 5 minutes. The siRNA mixture was then 
added dropwise onto the RNAiMAX mixture. Cells were then lifted, suspended in 5% 
FBS media, and counted. 400,000 cells in 2 mL media per well were then added on 
top of the siRNA mixture. 4-6 hours later, the media was removed, and complete 
media was added. 
 
Virus production and transduction 
 In order to make virus for transduction, 293T cells were plated in 10cm plates at 
1.5x106 cells per plate. The next day, 5µg of the lentiviral plasmid ptfLC3, which 
contained LC3 fused to a EGFP+RFP tag, was combined with 2.5µg of the pMD2.G 
(Addgene) envelope plasmid and 2.5µg of the psPAX2 (Addgene) packaging 
plasmid, into 250µL of DMEM SFM, per 10cm plate. Separately, 30µL of 
Lipofectamine 2000 (Thermo Fischer) was incubated in 250µL DMEM SFM. After 5 
minutes, the lentiviral combination was pipetted onto the Lipofectamine solution 
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dropwise. This mixture was then incubated for 20 minutes, then added dropwise onto 
the 293T cells. After 4 hours, the media was changed to 10mL DMEM+15% 
FBS+0.1% gentamycin. After 3 days, the media was harvested, and passed through 
a 0.45µm filter, then added to the cell type that would be transduced. Two days later, 
the media was changed to that which matches the transduced cell type. 
 
Cellular Function Assays 
For both cell lines, cells were subject to an initial siRNA transfection at 50% 
confluency in a 6-well plate, followed by a reverse transfection using 400,000 cells 3 
days later. 2 days after the reverse transfection, cells were harvested for analysis. 
For the proliferation assay, Click-iT EdU Alexa Fluor 488 assay (Thermo Fischer) was 
employed. Cells were incubated with washed with 10µM EdU for 1 hour, then fixed 
using 3.7% formaldehyde and permeabilized using 0.5% Triton X-100. Alexa Fluor-
488 was then added, and flow cytometry was performed on cells to quantify the 
percent of cells that stained positive for EdU-Alexa Fluor-488 as a readout for 
proliferation. For cell cycle assay, the same batch of cells used for the proliferation 
assay were incubated in DAPI for 5 minutes, then flow cytometry for DAPI staining 
was used to quantify the stages of cell cycle for each cell population. The apoptosis 
assay was performed using the FITC Annexin V Apoptosis Detection Kit I (BD 
Biosciences). After being stained with FITC and Annexin V, cells were sorted based 
on staining to quantify percent of population in early stage and late stage apoptosis. 
For colony formation assay, 50,000 UOK111 and H1975 cells were transfected with 
siRNA as described, then transfected again two days later. The next day, the cells 
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were lifted and counted. They were then plated in a 6-well plate at 1,000 cells/well. 
They were left to grow for seven days, then fixed with ice-cold methanol for one hour, 
then stained in 1% crystal violent (Sigma Aldrich) in methanol for 45 minutes. The 
colonies were then counted by eye using a hemocytometer. Each group was plated 
in triplicate. For the CARD11 overexpression colony formation assay, 50,000 A498 
cells/well were plated in a 6-well plate, then transfected with 1µg of empty vector 
pcDNA3.1 or pcDNA3.1-CARD11 vector. The next day, the cells were lifted, counted, 
and plated in a six-well plate at 1,000 cells/well. The group with Torin2 treatment had 
either DMSO vehicle or 150µM Torin2 added once the cells had attached. The colony 
formation assay was then conducted in the same manner as described above. 
 
Quantitative Reverse Transcriptase PCR 
RNA was extracted from cells using the Direct-zol RNA isolation kit (Zymo). Briefly, 
cells were washed with PBS, then re-suspended in TRIzol (Thermo Fischer), then run 
through a column, as instructed by the Direct-zol protocol. RNA was quantified using 
NanoDrop, then 500ng of RNA was used as a template for cDNA synthesis using the 
cDNA synthesis kit (Thermo Fischer). 25ng of cDNA was then used for qPCR 
analysis. Briefly, in each 96 well, 1µL of 100µM primer was added to 5µg cDNA and 
5µL SYBR Green PCR Master Mix (Thermo Fischer). This mixture was then placed 
in the rt-PCR machine (Applied Biosystems), and the following program was 
undertaken: 50°C 2 minutes, 95°C 10 minutes, (95°C 15 seconds, 60°C 1 minutes) x 
40 cycles. The Ct values were then compared, and the ΔΔCt was calculated. This 
was then used to quantify the relative changes in mRNA expression across samples. 
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Autophagic Flux Assay 
Cells were first transfected with siRNA, then subject to reverse transfection, as 
outlined above. Two days after reverse transfection, 200nM of Bafilomycin A1 (Sigma 
Aldrich) was added to complete media. Cells were incubated with Bafilomycin A1-
containing media for 4 hours, then protein was harvested, and run on an SDS-PAGE 
gel as outlined above. LC-3B (cleaved vs uncleaved) was determined by probing the 
membrane with anti-LC3B antibody. 
 
Live Cell Microscopy 
In order to measure differences in autophagic flux after knockdown of CARD11, 
100,000 UOK111 cells expressing GFP/RFP-tagged LC3 were transfected with 
CARD11 siRNA as listed above, then reverse transfected and plated on a 2-well 
chamber slide. One day later, cells were imaged using confocal fluorescent 
microscopy. Eight spots for control and treatment group that were similar in number 
of cells and fluorescent intensity were selected for imaging. A picture of each region 
was taken every 15 minutes. After 48h, the pictures were analyzed. Levels of late-
stage autophagy were quantified by using ImageJ to quantify the amount of RFP 
expression within the cells. Additionally, the morphologies of the cells were evaluated 
by eye. 
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In vivo mouse model 
500,000 A498 cells were plated in a 10cm dish. The next day, they were transfected 
with 7.5µg of either pcDNA3.1 empty vector, or CARD11-pcDNA3.1. One day later, 
1mg/mL of G418 sulfate was added for selection. The cells were grown in G418 
sulfate for 5 days, then 5x106 cells were injected subcutaneously into the right flank 
of athymic nude mice. The tumors were allowed to grow until the mice became 
moribund, then were harvested for molecular and immunohistochemical analysis. 
 
DNA Methylation Analysis 
Cells undergoing methylation analysis had their whole genome DNA isolated using 
the DNeasy Blood & Tissue kits. 500ng of DNA was then subject to bisulfite treatment 
using the EZ DNA Methylation-Direct Kit (Zymo). PCR was then performed on the 
bisulfite-treated DNA using the method as described above. In order to differentiate 
between methylated and unmethylated CpG dinucleotides, primers for each CpG 
were designed with their 3’ end falling on the CpG of interest. The primers probing for 
umethylated CpG had the 3’ end of their sequence be complementary to TpG, 
whereas the primers probing for methylated CpG were complementary to CpG, 
because after bisulfite treatment, all unmethylated CpGs become TpGs. The ΔΔCts 
of the PCR for each primer were then compared to determine relative levels of 
methylation in the cell population.  
 
Overexpression Constructs 
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To overexpress the CARD11 natural antisense transcript, the cDNA of the spliced 
transcript was synthesized and inserted into the pMX vector by GeneArt. This plasmid 
was amplified in DH5α competent E. coli (Thermo Fischer) by adding 50ng into 50µL 
bacteria, incubating on ice for 30 minutes, incubating at 42°C for 45 seconds, then 
put on ice for 2 minutes. 50 µL of LB broth (Thermo Fischer) was then added, and 
cells were incubated for 1 hour at 37°C. Cells were then spread on an agar plate 
containing ampicillin. The plate was then incubated overnight, and colonies were 
picked the next morning. Colonies were grown in 3mL of LB broth for 8 hours, then 
transferred to 50mL of LB broth for 6 hours. Cells were then spun at 4,000xg for 15 
minutes at 4°C, then the plasmids were isolated from the cell pellet using the QIAGEN 
midiprep kit. Plasmids were suspended in 50µL water, then quantified using 
NanoDrop (Thermo Fischer). 500ng of plasmid was digested with 2uL of EcoRI 
(Thermo Fischer) for 45 minutes. The digested product was run on a 1% agarose gel, 
and the band matching the size of the CARD11-NAT cDNA sequence was cut out 
and isolated using the QIAquick Gel Extraction Kit (Qiagen). Additionally, 500ng of 
the PCRII expression vector was cut with EcoRI, run on a gel, and isolated as 
described above. The cut PCRII vector and CARD11-NAT cDNA were then added 
together with 1uL T4 DNA ligase for 1 hour at 37°C, then transformed into DH5α cells 
as described above in order to obtain a PCRII construct with CARD11-NAT cDNA 
inserted within. 
 The CARD11 overexpression construct was ordered from Addgene (#44431), 
as well as the control empty vector pcDNA3.1. 
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Cas9-Tet1 fusion construct 
The nickase-dead dCas9-VP64-T2A-GFP plasmid was ordered from Addgene 
(plasmid 61422). The VP64 was replaced by the TET1 catalytic domain using the 
following primers:  
hTet1_CD_BamHI_F: ATTAGGATCCCTGCCCACCTGCAGCTGTCTT  
hTet1_CD_NheI_R: ATTAGCTAGCGACCCAATGGTTATAGGGCCCC 
The PCR product was amplified using DNA isolated from HT-29 colorectal cells using 
the method described above, as these cells contain high TET1 expression. The 
program consisted of 95°C for 2m(95°C for 15s60°C for 15s68°C for 45s)x30 
cycles68°C for 5m. This product as well as the dCas9 plasmid were cut using BamHI and 
NheI (Fermentas). Both were run on a 1% agarose gel, and the bands were isolated using a 
gel purification kit (Qiagen). The products were then incubated together with T4 ligase (NEB) 
at a 1:3 vector to insert ratio. This was then transformed into competent E.Coli and plated on 
an agarose plate containing ampicillin. The next day, four colonies were selected and grown 
in LB broth. After 8 hours, the culture was harvested and the plasmid was isolated using 
miniprep kit (Qiagen). The plasmid was then checked for proper insertion using the restriction 
digestion method described above. Once confirmed, the E.coli clone was grown in 50mL LB 
broth and the plasmid was isolated by midiprep kit (Qiagen). Virus was created from this 
plasmid using the method described above. H1975 cells were then incubated in viral media 
for 48h, then were replenished with normal media. After 7 days, these cells were sorted using 
flow cytometry for GFP expression. Those cells collected from this sort were checked for 
Cas9-Tet1 fusion protein expression by western using the Cas9 antibody (CST). Short 
guiding RNAs against the region of interest were selected using the Broad Institute 
CRISPRko design tool. These sgRNA were cloned using the SAM target sgRNA cloning 
58 
 
protocol. Site-specific methylation was evaluated using the DNA methylation direct kit as 
described above. 
 
TCGA Tissue Selection  
For this analysis, we worked with 10 tissue types with both tumor and normal samples 
with Illumina HiSeq RNASeqV2 and Illumina HumanMethylation 450k data available 
at the time of our initial download March 26, 2013 that had no publication restrictions 
according to the TCGA data policy 
(http://cancergenome.nih.gov/publications/publicationguidelines). These tumor types 
include bladder, breast, colon and rectal, head and neck squamous, kidney renal cell, 
liver, lung adeno, lung squamous, prostate adeno, thyroid, and uterine carcinomas. 
The corresponding clinical data used for the survival analysis was downloaded from 
the TCGA data portal current as of January 8, 2014. 
 
Description of the methylation and gene expression data 
According to the TCGA description file associated with the llumina Human 
Methylation 450K array data, probes having a SNP within 10 nucleotide base pairs 
(bp) of the interrogated CpG site or having 15 bp from the interrogated CpG site 
overlap with a REPEAT element are masked as NA across all samples. There are 
88058 probes that interrogate such sites (18.3% of all probes).  While these beta 
values are not reported at Level 3, the methylated (M) and un-methylated (U) intensity 
values for these probes are recorded in the Level 2 data. Therefore, we used the 
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Level 2 data to reconstruct the beta values for all probes as M/(M+U), also used by 
TCGA.   
For gene expression data, we worked with the log2 transformed Level 3 RNASeqV2 
data. To avoid errors for RNASeq raw counts of 0, all values are offset by 1 prior to 
taking logs. 
 
Methylation-expression correlation 
All analyses were performed using R, version 2.15.1. Using the complete set of 
probes targeting CpG dinucleotides, we performed a genome-wide analysis exploring 
the relationship between the proportion of methylation at various locations within and 
up to 1,500 bp upstream of a gene and the corresponding log transformed gene 
expression. We used the Spearman rank statistic to quantify the correlation for each 
pair. Because we expected these patterns to vary by tissue source site, we calculated 
coefficients individually using each of the 10 tissue types for which we had data from 
both the 450k methylation and RNASeq arrays.  
 
Survival analysis 
Tests for differences in survival were performed by comparing the overall survival of 
cancer patients in the top and bottom quartiles of 3’UTR methylation using the 
‘survival’ package in R for all genes with correlations >0.5 between gene expression 
and methylation at the 3’UTR for each tissue type. 
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Pathway analysis 
The pathway enrichment analysis was performed using Netwalker 
(http://www.netwalkersuite.org) on all genes with correlations >0.5 between gene 
expression and methylation at the 3’UTR, and <0.5 correlation between gene body 
methylation and gene expression, for each tissue type. An additional pathway 
analysis was run using Ingenuity Pathway Analysis (IPA, 
http://qiagenbioinformatics.com/products/ingenuity-pathway-analysis.com), which 
yielded similar results. 
 
Network Identification and Construction 
The network notes were obtained using Netwalker to determine how many nodes 
exist, and how the genes interact with one another. The resulting singular network 
node was identified from this method, and genes that have been shown to be 
associated with one another, but did not show up within the Netwalker database, were 
also isolated, then the node and other genes that associate it were exported to 
Cytoscape (https://www.cytoscape.org/). Connections were then manually included 
in Cytoscape based on published literature (234). 
 
T cell Isolation, Activation, and Demethylation 
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The spleens of C57Bl/6 mice were excised, then ground on a 40µm filter while being 
repeatedly washed with RPMI (Sigma-Aldrich)+10% heat-inactivated FBS (Thermo 
Fischer Scientific)+1%PenStrep (Thermo Fischer Scientific)+0.01% Beta-
Mercaptoethanol (Sigma-Aldrich). The resulting slurry was spun down at 4°C at 
450xg for 5 minutes, supernatant was removed, then the pellet was washed with 
50mL PBS (HyClone). The pellet was then incubated at room temperature for 5 
minutes using 4mL ACK lysis buffer (Gibco), then washed with 50mL PBS and spun 
down at 4°C at 450xg. The pellet was then re-suspended in the media listed above. 
To obtain naïve T cells, cells were sent immediately for flow cytometry cell sorting. 
To activate the T cells, 2µL/mL of mouse CD3e (BD Biosciences) and 3.5 µL/10mL 
mouse CD28 (BioXCell) activating antibodies were added to the media, along with 
1:10,000 100ng/µL mouse recombinant IL-2 (R&D Systems). To induce 
demethylation, activated T cells were treated with 500nM of 5’deoxy-azacytidine 
(Sigma-Aldrich) for 72h, or vehicle DMSO control. 
 
Flow Cytometry 
Spleen cells were grown in the conditions as outlined above were spun down at 450xg 
at 4°C for 5 minutes to pellet cells. The supernatant was removed, then cells were re-
suspended in 2mL FACS buffer (PBS+2%FBS). Cells were then spun at 450xg at 
4°C for 5 minutes. Supernatant was again removed, and cells were re-suspended in 
200µL FACS buffer + 2µL mouse CD16/CD32 blocking antibody (BD Biosciences) 
and incubated on ice for 10 minutes. After incubation, 2µL each of mouse CD45-PE, 
CD4-eFlour 450, and CD8-APC-eFluor 780 (eBiosciences) were added, then cells 
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were incubated on ice for 30 minutes. All cells that were either CD45+ & CD4+, or 
CD45+ and CD8+, were sorted by flow cytometry and collected for molecular 
analysis. 
 
Quantitative Polymerase Chain Reaction 
Specimens were collected from flow cytometry, spun down at 450xg for 5 minutes at 
4°C, then re-suspended in 350µL TRIzol (Thermo Fischer). RNA was isolated from 
specimens using the Direct-zol RNA Isolation kit (Zymo), and quantified by 
NanoDrop. 100ng of RNA was used for a cDNA template. cDNA was created using 
the Verso cDNA synthesis kit (Invitrogen). 5µg of cDNA was combined with 1µL of 
100µM forward and reverse primers, and 5µL of SYBR Green PCR Master Mix 
(Thermo Fischer) each well. The resulting mixture was then run in a real time PCR 
machine (Applied Biosystems) using the following program: 50°C 2 minutes, 95°C 10 
minutes, (95°C 15 seconds, 60°C 1 minutes) x 40 cycles. The resulting Ct values 
were then compared, and the ΔΔCt was obtained. This was used to quantify the 
relative change in mRNA across samples. 
 
Primers 
qPCR primers: 
Havcr2 F CTCCAAGAACCCTAACCACG 
Havcr2 R AGCCCATGTGGAAATTTTTG 
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Itk F TGTCTTAACGAAAGCCAGCC 
Itk R TCCACACACTTGATTCTGGAG 
Vav1 F TTCCCCAGGCCATTAATCTT 
Vav1 R GCCGAACTTCTCACAGCAA 
 
Methylation analysis primers: 
mVAV/Fbio2  AGTTTGTTATTGATGGAAGTTAG  
mVAV/R2  ACATAAAACCAATAATAAACCAATAAA  
mVAV/S2  CCAATAAAAACATCCCC  
mITK/Fbio1  TTGTTTATTTTTTTTTGGGAAATTTT  
mITK/R1  TCCTAAACCACACCACAAACTT  
mITK/S1  CACCACAAACTTCTCT  
mITK/F2  ATTTTTGGGATATTTAATTTGGAAGATA  
mITK/Rbio2  TCTATAAACACAAAACACCATTTACAA  
mITK/S2  GGTGGTATTGGTTTTTTTAA  
mHAVCR2/F1  AGTATTTAGAAGGTTGGAGTAGA  
mHAVCR2/Rbio1  TTCCCCTTAAACACACAACAAT  
mHAVCR2/S1  TTTTTTATAGAAGAAAAAGGTTAT  
mHAVCR2/F2  TGTGTTTAAGGGGAATTGATTTAGATA  
mHAVCR2/Rbio2  ACTATAAACCAAATAAAACTAAAATCCAC  
mHAVCR2/S2  GGAGTTGTTTTTGATAGAAGA  
mHAVCR2-E/F1 AGGGTTGGTAAATGTAGGAGTA  
mHAVCR2-E/Rbio1 ACCTCCAATAAAATTACCAAATAACAT  
mHAVCR2-E/S1 AGGATTAGTTTTGAGGAAAATATT  
mHAVCR2-P/F1 GGGGATTTAGGAGTTAGAGGAAGT  
mHAVCR2-P/Rbio1 AAAAAAACCCAAACCCAAACTT  
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mHAVCR2-P/S1 GGAGTTAGAGGAAGTATTA  
mHAVCR2-I/F1 GTAGTGTTATAGGGTTATAGTGATAGAGTT  
mHAVCR2-I/Rbio1 TACATATACCAAAACCAACTAAAAAATCA  
mHAVCR2-I/S1 TTATTGTTGAGGATAGTATATAA  
 
 
Methylation analysis 
One microgram of genomic DNA was treated with sodium bisulfite using the 
EZ DNA Methylation-Gold Kit (Zymo Research, Irvine, CA) according to the 
manufacturer’s protocol. The samples were eluted using 40µl of M-Elution Buffer, 
then 2µl of the eluted product were subjected to PCR analysis. The pyrosequencing 
analysis as well as the bisulfite conversion were carried out at the DNA Methylation 
Analysis Core, UT MD Anderson Cancer Center. 
The Pyromark Assay Design SW 1.0 (Qiagen) software was used for design 
of the Havcr2, Itk, and Vav1 primers. These primers were designed using the 
following parameters: approximately 5bp away from the CpG to be analyzed, a primer 
with an annealing temperature of within 5°C of 40°C was designed for sequencing. 
Next, two primers representing the forward and the reverse flanking the sequencing 
primer were created. To determine the best annealing temperature, gradient PCR 
was performed. The combined volume totaled to be 20µL, and all 20µL was employed 
for a single reaction, as described (235). Streptavidin-sepharose high-performance 
beads (GE Healthcare Life Sciences) were used in purification of the PCR product. 
The biotinylated products of the PCR reaction and primer used for sequencing 
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(3.6pmol per reaction) were then co-denatured using the guide for sample 
preparation (PSQ96). The sequencing was then carried out using a PyroMark Q96 
ID instrument. The reagents used for this reaction are the Pyromark Gold Q96 variety 
(Qiagen). The PyroMark Q96 software was used to determine the amount of 
methylation for each analyzed CpG. In each sample, the methylation average, as well 
as the duplicates, were recorded. 
 
 
 
 
Overarching Hypothesis and Specific Aims 
 
Hypothesis: DNA methylation at sites outside the promoter is critical for cancer 
pathogenesis. Targeting these sites will result in decreased tumorigenesis and 
tumor progression. 
 
Specific Aim 1: To Inivestigate the relationship between non-promoter DNA 
methylation and gene expression in genes relevant to cancer 
Specific Aim 2: To determine the function(s) of relevant sites of non-promoter DNA 
methylation 
Specific Aim 3: To elucidate the molecular and cellular consequences of gene 
body DNA methylation on cancer pathogenesis 
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Results 
 
Section 3: Identification of methylation sites correlated with gene expression, 
and investigating the function and regulation of CARD11 in cancer 
 
Methylation is the most common DNA modification in the genome, and plays 
an important role in regulating gene expression. This process is a critical means by 
which cells containing the exact same DNA template can differentiate into a 
spectacular array of different cell types and functions. The most studied type of DNA 
methylation is that which occurs on CpG islands within a gene promoter region. This 
has been shown to powerfully repress transcription through multiple mechanisms, 
particularly through inducing formation of heterochromatin by recruiting histone 
modifiers. However, promoter DNA methylation only accounts for a tiny fraction of 
genomic methylation. Recent studies have begun to unravel the impact of DNA 
methylation outside of the promoter region. Enhancer, gene body, and intergenic 
DNA methylation have all been implicated in various forms of gene regulation. 
Despite these recent advancements, much remains to be understood about region-
specific DNA methylation. 
Because DNA methylation is essential for numerous cellular functions, 
aberrant DNA methylation is frequently observed in a huge variety of unrelated 
diseases. This phenomenon has been implicated in conditions such as 
neurodegenerative disorders, cardiovascular disease, autoimmune disease, and 
many others. Most prominently, aberrant DNA methylation is closely tied to cancer 
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pathogenesis. Since cancer involves a fundamental alteration of a cell’s 
developmental state, global changes to DNA methylation are ubiquitously observed 
across nearly every type of cancer. These changes are involved in early phases of 
tumorigenesis through cellular de-differentiation, suppression of tumor suppressor 
genes, and enhanced expression or reduced repression of oncogenes. Furthermore, 
changes to the DNA methylome have been causally linked to metastasis, 
emergence/maintenance of chemoresistance, and alterations to the tumor 
microenvironment.  
Considering the immense involvement of this epigenetic modification on 
cancer formation and progression, elucidating how changes to the DNA methylome 
drive these oncological outcomes is critical for a greater understanding of these 
deadly diseases. Moreover, investigating how aberrant DNA methylation occurs is 
crucial for designing novel therapeutic approaches. In particular, gene body 
methylation has emerged as a major player in cancer pathogenesis. Contrary to 
promoter DNA methylation, this modification has been shown to promote gene 
expression by multiple mechanisms, depending on the specific locus and context. For 
example, DNMT3B-mediated gene body methylation, especially within myc-regulated 
genes, has been demonstrated to activate oncogenes in colorectal cancer. Despite 
these recent advances, little is understood about how gene body methylation is 
intertwined in cancer pathogenesis. 
 
Subsection 3.1: The T- and B-cell specific gene CARD11 has robust correlation 
between gene expression and gene body methylation in 19 of 32 cancer types. 
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To address the question of how gene body methylation plays a role in cancer 
pathogenesis, the following analysis was performed: the correlation between gene 
body methylation and gene expression of a list of highly likely tumor suppressors and 
oncogenes (236) across 32 tumor types were examined. Those genes with a 
correlation coefficient of > 0.5 between gene body methylation and gene expression 
in at least one tumor type were selected. The gene that matched this criterion in the 
highest number of tumors, CARD11, was found to have highly correlated gene body 
methylation and gene expression in 19 of the 32 tumor types examined (Fig26.). 
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Figure 26: Heat map of all high confidence cancer-related genes that have a correlation 
coefficient of >0.5 (represented by red boxes) between gene body methylation and gene 
expression across 32 cancer types.  
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Based on this striking observation, the impact of CARD11 was examined in 
more detail. This gene is expressed in T and B cells, and functions as a scaffold 
protein that links activation of the T and B cell receptors to the downstream effector 
pathway NF-kB (237, 238) (Fig27.).  
 
 
 
Figure 27: CARD11 is phosphorylated after B- and T-cell receptor activation, causing 
oligomerization and recruitment of Bcl-10/MALT1 complex, which induces degradation 
of IKK, causing NFkB activation. <Taken with permission from Gastric MALT lymphoma: 
a model of chronic inflammation-induced tumor development. Sagaert 2010 Nature 
reviews(3)> 
71 
 
 
 
CARD11 is well-known to be a driver of diffuse large B cell lymphoma, in which 
activating mutations drive constitutive NF-kB activation, leading to pro-cancerous 
effects(239), but its role in epithelial cancers has never been explored. To address 
this, the difference in expression of CARD11 between 15 of the most common 
epithelial cancers and their corresponding normal tissues was evaluated using TCGA 
datasets. This analysis revealed that CARD11 is significantly overexpressed in 9 of 
the 15 tumor types, most substantially in kidney renal cell carcinoma (KIRC) and lung 
adenocarcinoma (LUAD) (Fig28.). 
 
 
Figure 28: Expression of CARD11 in normal versus tumor in 15 tumor types. KIRC and LUAD 
show the greatest difference in expression when comparing normal and tumor samples. 
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 The association between CARD11 expression and patient overall survival was then 
evaluated by determining the Z-score between expression and overall survival. The 
Z-score tells us how many standard deviations above the mean a group is. In this 
case, the CARD11 gene expression of patients that were in the bottom quartile of 
survivors was compared to the mean. This revealed that high expression is strongly 
correlated with shorter patient survival in KIRC, with a Z-score of approximately 4 
(Fig29.. Of note, BRCA and BLCA showed the opposite effect, indicating tissue-
specific effects of CARD11 expression on overall survival. 
 
Figure 29: Z-score of CARD11 expression in 32 tumor types. KIRC has a z-score of nearly 4, 
indicating that CARD11 expression may negatively impact patient overall survival. 
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Plotting gene expression of CARD11 on a Kaplan-Meier curve revealed that patients 
who overexpress this gene had significantly lower overall survival, relative to those 
who expressed CARD11 at a low level, in KIRC (Fig30.).  
 
 
 Figure 30: Patient overall survival in those patients with the highest 20% of CARD11 
expression versus the lowest 20%. High expression of CARD11 is associated with 
shorter overall survival. 
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These data indicate that expression of CARD11 is highly correlated with 
methylation of the gene body, that higher expression is observed in 9 of 15 epithelial 
tumor types examined, and that overexpression of CARD11 may negatively impact 
survival of patients with KIRC. 
 
Subsection 3.2: CARD11 regulates autophagy in kidney renal cell carcinoma 
and lung adenocarcinoma through the mTOR pathway. 
Given the observed overexpression of CARD11 across numerous epithelial 
cancers, and considering that expression of CARD11 is inversely correlated with 
patient overall survival in KIRC, an investigation into the functional impact of CARD11 
expression in epithelial cancers, as well as the mechanistic underpinning, was 
undertaken. CARD11 is an adaptor protein which links stimulation of the T and B cell 
receptors to activation of the NF-kB pathway. Because CARD11 is known to impact 
cellular signaling, an RPPA was conducted in which CARD11 was knocked down 
 
siCon
triplicate
siCARD11
triplicate
CARD11
GAPDH
Figure 31: Western blot of the knockdown efficiency of CARD11 
protein in the samples used for RPPA. 
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using siRNA in the H1975 lung adenocarcinoma cell line, which contains high 
expression of CARD11 (Fig31.). 
According to the RPPA, contrary to expectations, the NF-kB pathway remained 
unchanged after CARD11 knockdown (Fig32.). 
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 Figure 32: RPPA heatmap comparing siControl vs siCARD11(bottom 3 rows) in H1975 lung adenocarcinoma cells that shows 
upregulated (red) or downregulated (green) genes. 
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To determine which pathway was most impacted by knockdown of CARD11, 
the changes to protein expression and phosphorylation detected by RPPA were 
analyzed using the NetWalker platform. This demonstrated that the pathway most 
affected by knockdown was the mTOR pathway (Table 1). 
 
 
 
 
 
Table 1: NetWalker analysis of the top pathways 
affected by CARD11 knockdown in H1975 lung 
adenocarcinoma cells. 
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 The mTOR pathway as the control center of cell growth, can affect a multitude 
of cellular processes, ranging from metabolism, to transcription, to autophagy(240).  
Therefore, the impact of CARD11 on the functions involved in cancer pathogenesis 
were measured. To find the most optimal renal cell carcinoma cell line for studying 
the effects of CARD11, a panel of renal cell carcinoma lines were probed for CARD11 
protein expression by western blot. This revealed that UOK111 contained the highest 
expression of CARD11 among these cell lines (Fig33.); therefore, UOK11 was 
selected for further analysis. 
Figure 33: Cell panel of 8 KIRC lines to determine which cell line contained the highest 
expression of CARD11. 
 
CARD11
GAPDH
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CARD11 has been shown to be necessary for proper mTOR activation in 
lymphocytes (188), so to confirm this role in epithelial cancers as well, H1975 cells 
and UOK111 renal cell carcinoma cells were transfected with CARD11 siRNA or 
control siRNA. S6, a downstream node of the mTOR pathway that showed decreased 
activation at both major phosphorylation sites from the RPPA, was probed for 
phosphorylation as a measure of activation. After CARD11 knockdown, the amount 
of phosphorylated S6 decreased in both UOK111 and H1975 cell lines (Fig34.), 
validating the finding that the mTOR pathway is positively regulated by CARD11. 
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Figure 34: The phosphorylation state of the S6 ribosomal protein, a downstream 
component of the mTOR pathway that was shown by RPPA to be decreased after 
CARD11 knockdown. 
H1975 UOK111 
CARD11 
GAPDH 
pS6 
Total S6 
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UOK111 and H1975 cells were subject to proliferation and cell cycle assays after 
CARD11 knockdown, however, no significant change in either of these processes 
was observed (Fig35.).  
 
 
 
Figure 35: UOK111 (top) and H1975 (bottom) showed no significant difference in cell 
cycle (left) or proliferation (right) after CARD11 knockdown. 
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Next, the rate of apoptosis was determined after CARD11 knockdown, but 
there was no difference between control siRNA and CARD11 siRNA groups. Finally, 
the ability of the cells to establish single-cell colonies after CARD11 knockdown was 
measured. Both UOK111 and H1975 cell lines showed a significantly impaired 
capability of forming colonies after CARD11 knockdown (Fig36.).  
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Figure 36: UOK111 (top) and H1975 (bottom) showed no significant difference in 
apoptosis (left) after CARD11 knockdown; however, both cell lines exhibited 
significantly diminished numbers of colonies formed (right) after CARD11 knockdown. 
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Conversely, the KIRC cell line A498, which does not express CARD11, was 
transfected with a CARD11 overexpression plasmid. This resulted in a nearly 4-fold 
increase in colony formation. Furthermore, treating the A498 cells with Torin2, an 
mTOR inhibitor, abrogated the increase in colony formation of the CARD11 
overexpressing line, relative to the empty vector-transfected line (Fig37.). This 
supports the conclusion that CARD11-mediated mTOR activation is important for the 
observed capacity of cancer cells to form colonies. 
 
Figure 37: (Top) CARD11 protein expression increases pS6, and treatment with 50nM 
Torin2 abrogates S6 phosphorylation(Left) CARD11 protein overexpression confirmed by 
western blot. (Right) Overexpression of CARD11 in A498 KIRC cells resulted in a three-
fold increase in number of colonies, whereas treating with mTOR inhibitor Torin2 
reduced the difference in number of colonies formed between empty vector and 
CARD11 overexpressing groups. EV= empty vector; CARDOX=CARD11 
overexpression. 
 
 
CARD11
Phospho S6
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mTOR activation negatively regulates autophagy during situations in which the 
cell has access to nutrients and can grow and divide. However, autophagy is 
activated in stressful situations such as when isolated as single cells such as in a 
colony formation assay, to allow the cells to survive. Furthermore, diminished 
autophagy is known to play a role in renal cell carcinoma pathogenesis(241). Based 
on this rationale, expression of CARD11 was hypothesized to decrease autophagy. 
To test this hypothesis, the level of autophagy in UOK111 cells after CARD11 
knockdown was determined using lipidated LC3 as a marker. CARD11 knockdown 
resulted in increased amounts of lipidated LC3 in both cell lines tested(Fig38.). 
 
Figure 38: Knockdown of CARD11 results in 
increased lipidated LC3 in UOK111 (left) and 
H1975 (right) cells.  
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Because an increase in lipidated LC3 can be due to increased autophagy, or 
to decreased fusion of the autophagosome with the lysosome, the fusion inhibitor 
bafilomycinA1 was employed to ascertain the cause of increased lipidated LC3. If 
fusion was compromised, the addition of bafilomycinA1 should not result in any 
change in lipidated LC3 after CARD11 knockdown. However, after adding 
bafilomycinA1, the amount of lipidated LC3 increased substantially in CARD11 siRNA 
cells, indicating that knocking down CARD11 causes increased autophagy in 
UOK111 (Fig39.). 
 
Figure 39: In UOK111, knockdown of CARD11 causes increased lipidated LC3 
(bottom band), indicating an increase in autophagy. Treatment with Bafilomycin 
further increases lipidated LC3, indicating that autophagic flux has increased after 
CARD11 knockdown, rather than a decreased ability for autophagosomes to fuse 
with lysosomes. 
siControl siCARD 
#1
siCARD 
#2
CARD11 
LC3 
GAPDH 
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Similar results were observed in H1975 LUAD cells, in which knockdown of CARD11 
caused an increase in lipidated LC3, and treatment with bafilomycin in this context 
resulted in even greater accumulation of lipidated LC3, suggesting that the impact of 
CARD11 knockdown on autophagic flux was not limited to a singular tumor type (Fig
40.). 
 
siControl siCARD #1 siCARD #2
CARD11
LC3
GAPDH
Figure 40: In H1975, knockdown of CARD11 causes increased lipidated LC3 (bottom 
band), indicating an increase in autophagy. Treatment with Bafilomycin further 
increases lipidated LC3, indicating that autophagic flux has increased after CARD11 
knockdown, rather than a decreased ability for autophagosomes to fuse with 
lysosomes. 
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To further test this hypothesis, a GFP/RFP-tagged LC3 protein was expressed 
in UOK111 cells, allowing for visualization of autophagic flux. When the 
autophagosome forms, the GFP fluorescence of LC3 is converted into RFP. 
Therefore, the red punctates within a cell represent the level of late-stage autophagy. 
After transfecting UOK111 cells, they were sorted for expression of GFP. The cells 
received from this sort were then subject to transfection of control siRNA or CARD11 
siRNA. Two days later, they were again transfected, and plated in a slide that allows 
for visualization. One day later, the autophagy levels of the cells were visualized using 
live cell confocal microscopy. In order to best compare these two groups, two regions 
in which both groups had low RFP expression were selected to record. Cells were 
then recorded for 48 hours, and the changes to RFP expression and localization, as 
well as the cell morphology, were examined. The control siRNA-treated cells 
remained healthy, and showed low RFP-labeled punctates, whereas the CARD11 
siRNA-treated cells had high numbers of RFP-labeled punctates form, and showed 
high cell death after late-stage autophagy formation (Fig41.). This strongly supports 
the conclusion that CARD11 suppresses autophagy, and that knockdown of CARD11 
results in increased autophagic flux. 
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Figure 41: UOK111 cells were stably transfected with LC3-GFP/RFP as a measure of 
autophagic flux. RFP indicates that cells are undergoing late-stage autophagy. 
Knockdown of CARD11 resulted in a much greater proportion of cells to undergo late-
stage autophagy. 
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Subsection 3.3: CARD11 Natural Antisense Transcript does not regulate 
CARD11 expression. 
As noted, CARD11 gene body methylation is strongly correlated with gene 
expression. Therefore, to ascertain whether this modification is a driving factor in 
overexpression of CARD11 in epithelial cancers, gene body methylation in tumor 
samples or corresponding normal tissues was compared, revealing an increase in 
gene body methylation of CARD11 in KIRC, relative to normal tissues (Fig42.). 
However, this increase was not statistically significant. 
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Figure 42: Average of the top 10 most 
significantly CARD11 gene body methylation sites 
between normal and tumor. 
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Treating UOK111 cells with decitabine resulted in a decrease in CARD11 expression, 
supporting the notion that methylation increases its expression (Fig43.). 
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Figure 43: Treatment of UOK111 cells with decitabine resulted in a 30% decrease in CARD11 
expression. 
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 To understand how gene body methylation may be positively regulating 
CARD11 gene expression, the gene locus was analyzed using Santa Cruz Genome 
Browser. This revealed an unexplored natural antisense transcript (NAT) that falls 
within the last 2/3rds of the gene body (Fig44.). 
[Grab your reader’s attention with a great quote from the document or use this space to 
emphasize a key point. To place this text box anywhere on the page, just drag it.] 
Figure 44: CARD11 gene layout (taken from Ensembl). CARD11 gene body contains a 
natural antisense transcript (red box) composed of two exons and one intron. 
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Because NATs have been shown to commonly mediate site-specific DNA 
methylation, as well as to regulate expression of their corresponding sense transcript 
(242), this NAT was selected for further analysis. NATs can either positively or 
negatively impact sense gene expression (242); therefore, the first step was to 
investigate the correlation between CARD11 and CARD11-NAT. This revealed a 
robust positive correlation between this pair in every tissue type examined, including 
in KIRC and LUAD (Fig45., Table 2).  
 
 
 
  
Figure 45: CARD11 and its NAT are robustly correlated in both KIRC and LUAD. 
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Tissue Type Correlation 
BLCA 0.84 
BRCA 0.75 
CESC 0.70 
GBM 0.65 
HNSC 0.81 
KICH 0.77 
KIRC 0.75 
KIRP 0.82 
LAML 0.90 
LGG 0.69 
LIHC 0.62 
LUAD 0.80 
LUSC 0.79 
OV 0.83 
PAAD 0.65 
PRAD 0.71 
SKCM 0.81 
STAD 0.79 
THCA 0.83 
 
Table 2:  The correlation between 
CARD11 sense and NAT across 19 
tumor types. 
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Furthermore, CARD11-NAT expression across 11 tissue types was evaluated using 
TCGA datasets. This revealed that CARD11-NAT was overexpressed in 5 of the 11, 
with KIRC and LUAD having the most significant difference in expression between 
normal and tumor(Fig46.). 
 
 
 
 
 
Figure 46: Comparing expression in tumor versus normal of CARD11-NAT across 12 
tissue types. CARD11-NAT shows greatest difference in expression between normal and 
tumor in KIRC and LUAD. 
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Therefore, it was hypothesized that CARD11-NAT is positively regulating 
expression of CARD11 by promoting methylation of the CARD11 gene body. To test 
this hypothesis, TCGA samples for KIRC and LUAD were segregated based on high 
versus low expression of CARD11-NAT, and CARD11 methylation was compared 
between the two groups. This revealed that of 79 methylation sites examined, 31 
showed a significant difference in methylation in KIRC, and 63 showed a significant 
difference in LUAD. Within the gene body, 23 out of 25 loci in KIRC with differential 
methylation showed higher methylation in the samples with high CARD11-NAT. 
Likewise, 54 of 55 loci in LUAD with differential methylation showed higher 
methylation in the samples with high CARD11-NAT (Table 3). In particular, the 
probes displaying the most significant difference in methylation were located at a CpG 
island within the CARD11 gene body (Fig47.).  
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KIRC LUAD 
Total CARD11 DNA methylation probes 79 79 
# Significant difference in methylation based on 
CARD11-NAT expression 
31 (35%) 63 (80%) 
# Significantly differentially methylated loci within the 
CARD11 gene body 
25 55 
# of probes showing increased methylation in CARD11-
NAT High group 
23/25 54/55 
 
Table 3:  The difference in CARD11 gene body methylation after segregating samples based on high versus 
low expression of CARD11-NAT.  
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Figure 47: (Top) CARD11 layout (taken from Santa Cruz Genome Browser) showing a 
CpG island (red box) located approximately 2/3rds down the gene body. 
(Bottom) Expression level of CARD11-NAT (T317639) in relation to CpG island 
methylation. In both KIRC and LUAD, methylation of this region is associated with higher 
expression of CARD11-NAT.  
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To determine whether the correlation between high CARD11-NAT and high 
CARD11 gene body CpG island methylation is due to CARD11-NAT inducing DNA 
methylation, or vice versa, CARD11-NAT was knocked down using siRNA, then the 
methylation of the CARD11 CpG island was measured. This showed that knockdown 
of CARD11-NAT had no effect on the methylation of this locus (Fig48.).  
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Figure 48: Knockdown of CARD11-NAT did not impact the level of methylation of the 
CARD11 gene body CpG island. 
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Next, specific demethylation of the CpG island was induced by expressing a 
fusion protein consisting of Cas9 combined with the catalytic domain of Tet1, the 
enzyme responsible for DNA demethylation. Two guide RNAs were designed to 
target this fusion protein to the CpG island, and the Cas9-Tet1 fusion protein along 
with the sgRNAs were transduced into H1975 cells by lentiviral transduction to induce 
stable demethylation of this locus (Fig49.).  
 
Guide RNA
Cas9-Tet1
GAPDH
Figure 49: (Left) illustration of the Cas9-Tet1 fusion protein that allows for 
specific demethylation of a locus based on guide RNA binding. (Right) 
expression of the Cas9-Tet1 protein can be detected by western blot. 
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This resulted in a significant reduction of both CARD11 and CARD11-NAT 
expression, strongly indicating that CARD11-NAT is downstream of CARD11 CpG 
island methylation (Fig50.). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50: (Top) CARD11 CpG island methylation after specific demethylation. 
(Bottom) Expression of CARD11 (left) and CARD11-NAT (right) both exhibited a 
substantial decrease in expression after specific demethylation of the CARD11 gene 
body CpG island induced by Cas9-Tet1. 
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To determine whether the corresponding decrease in CARD11-NAT was the 
cause of decreased CARD11 expression after site-specific demethylation, CARD11-
NAT was overexpressed, and the expression of CARD11 was quantified by qPCR. 
This showed no difference in CARD11 expression after overexpression of CARD11-
NAT, suggesting that the methylation of this region is regulating CARD11 expression 
through an alternate mechanism (Fig51.). 
 
 
Therefore, this data discounts the hypothesis that the NAT regulates CARD11, and 
that the decrease in CARD11 after demethylation is due to decreased NAT 
expression.  
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Figure 51: Expression of CARD11-NAT (left) and CARD11 (right) after CARD11-NAT 
overexpression. Higher CARD11-NAT did not impact the expression of CARD11 in 
this context. 
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One alternate hypothesis that is currently under investigation is whether the 
intragenic CpG island is the location of a cryptic alternative promoter. Recent studies 
have identified a wide number of intragenic CpG islands as being methylated as a 
means of repressing aberrant downstream transcription initiation(243). In this context, 
gene body CpG island methylation results in increased transcription of the full-length 
mRNA; loss of methylation causes transcription to occur downstream, thereby 
inhibiting expression of the full length transcript. Furthermore, the CARD11 CpG 
island contains multiple binding sites for SP1, a transcription factor that is sensitive 
to DNA methylation. To test this hypothesis, the H3K9ac status of this region will be 
tested, which indicates when a specific site adopts the chromatic architecture of an 
actively transcribing promoter. Furthermore, the binding of SP1 to CARD11 gene 
body CpG island will be evaluated after demethylation. 
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Section 4: 3’UTR DNA methylation is a functionally relevant epigenetic 
modification distinct from gene body methylation, and plays a role in regulating 
T cell activation genes. 
 
Subsection 4.1: DNA methylation probes positively correlated with increased 
gene expression are enriched in 3’UTRs. 
The Cancer Genome Atlas (TCGA) provides a unique opportunity to harness 
large-scale molecular profiling datasets across numerous tumor types and over 
11,000 patient samples(244). In order to explore the relationship between poorly 
understood sites of DNA methylation and gene expression, genome-wide RNA-seq 
and methylation array datasets from this platform were utilized.  Initially, the 
proportion of probes achieving negative Spearman correlations of < -0.5 between 
gene expression and DNA methylation were examined within each of the 6 gene 
regions included in the Illumina methylation probe annotation after normalizing for the 
total number of probes interrogating each region. 
 
  We note that the sample sizes associated with TCGA are such that these 
correlations are essentially certain to be real (p <0.0004, assuming n=50). With 
sample sizes per tissue in excess of a few hundred, absolute correlations > 0.5 were 
considered highly significant for this analysis. Approximately a third of the strong 
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associations were positive (at the probe level there were 44,309 negative and 29,043 
positive associations; at the gene level there were 6,287 negative and 3,200 positive 
associations). As expected, the majority (> 75%) of the negatively correlated probes 
across all 10 tissue types were concentrated within the first exon, 5’-UTR, and 
upstream of the transcription start site (Fig52.).  
 
 
Figure 52: Proportion heat map representing the distribution of probes 
in which the correlation between methylation and gene expression was 
< -0.5 across 10 tissue types. 
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Upon segregating the positively correlated probes based on region, it was 
noted that approximately 3% of these probes were interrogating the 3’UTR. Gene 
body DNA methylation is a known feature of highly transcribed genes(245); however, 
previous studies have grouped the 3’UTR along with the rest of the gene body, rather 
than investigating it as a distinct region. To determine whether there existed a 
statistical rationale to separate the 3’UTR from the gene body, the proportion of 
probes within the 3’UTR that exhibited a positive correlation of > 0.5 between DNA 
methylation and gene expression was calculated (Fig53.). 
 
 
Figure 53: Proportion heat map representing the distribution of 
probes in which the correlation between methylation and gene 
expression was > 0.5 across 10 tissue types. 
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This revealed a substantial net enrichment in the proportion of positively correlated 
probes in the 3’UTR when compared to the entire gene region across all 10 tissue 
types (Fig54.), with up to 590 genes exhibiting a correlation coefficient of > 0.5 
between 3’UTR methylation and gene expression (Table 4). 
 
 
Figure 54: The arrows represent the directional change of the percentage of 
probes with negative correlations < -0.5 compared with the percentage of 
probes with positive correlations > 0.5 when evaluating the entire gene. The 
arrows in the southeast direction indicate an increase in the percentage of 
positive probes and a simultaneous decrease in the percentage of negative 
probes. In the case of LUSC, we observed a 5% increase in the number of 
positively correlated probes and a 3% decrease in the number of negatively 
correlated probes. There was enrichment in the percentage of positively 
correlated probes in the 3’UTR for all 10 tissue types. 
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BLCA 
Correlation 
Coefficient BRCA 
Correlation 
Coefficient2 CORE 
Correlation 
Coefficient3 
AASS 0.596732 ABLIM3 0.6087407 ABCA3 0.5134683 
ABCA2 0.5940652 ACE2 0.5152063 ABLIM3 0.5071737 
ABCA3 0.7429512 ADCY2 0.5784943 ALOX5 0.5318469 
ABLIM2 0.5834121 AGAP2 0.6427411 ANKRD5 0.5128174 
ABLIM3 0.6396832 AMH 0.5517516 BAHCC1 0.6107377 
ACOXL 0.6250692 ANO5 0.6308839 C10orf72 0.5160956 
ACSS3 0.5256172 ASAM 0.5539502 C17orf77 0.5037266 
ADAM33 0.520791 ASB2 0.5050138 C2CD4C 0.5362058 
ADAMTS17 0.5905777 ASPH 0.5151348 C6orf97 0.5073339 
ADAMTSL3 0.615171 ATP2B2 0.5260176 CADM3 0.5612771 
ADAMTSL5 0.603206 B3GAT1 0.5220495 CARD11 0.702967 
ADARB1 0.514069 BACH2 0.5025892 CD1D 0.5386125 
ADCY2 0.6243769 BAHCC1 0.5476259 CDO1 0.5375716 
ADCY9 0.6462192 BCL11A 0.5383716 CPE 0.6422394 
ADD2 0.5051489 BIVM 0.5357103 CPLX2 0.5389136 
ADH1B 0.5186804 BMP2 0.6188118 CRIP2 0.5943179 
ADORA1 0.5027623 BOC 0.5102699 CSNK2A1 0.5498119 
ADPRH 0.5103907 C10orf128 0.571714 CTXN1 0.542705 
ADRA1A 0.5428149 C10orf90 0.5685527 CUL4A 0.5009405 
AJAP1 0.5437472 C11orf21 0.5128085 DCDC2 0.6050958 
ALDH1L2 0.514923 C11orf63 0.5548425 DCLK2 0.5045169 
ALDH2 0.591384 C17orf51 0.6420734 DDX3Y 0.8002091 
AMOT 0.6702877 C17orf75 0.5039303 DGKG 0.5271233 
ANO5 0.5600789 C19orf18 0.5528789 DOCK2 0.5898943 
APBB1IP 0.5601641 C20orf160 0.550029 DOK2 0.5577691 
ARHGAP28 0.7179572 C8orf79 0.6529395 EIF1AY 0.7646542 
ARMC4 0.7332187 C9orf125 0.5540748 EMP3 0.5646654 
ARSJ 0.67742 CA8 0.5158163 FAM189A1 0.624909 
ASAM 0.6373837 CACNA1H 0.5302311 FBLN2 0.5505962 
ASB12 0.5004157 CADM3 0.6157453 FGF9 0.5290764 
ASB2 0.5098946 CAMK2D 0.5295647 FSCN1 0.5490571 
ATP10A 0.6582176 CBFA2T3 0.5951633 GABBR1 0.5036603 
ATP10B 0.5056743 CBLN2 0.5188389 GNA15 0.546698 
AXL 0.537961 CDK6 0.5623088 GPR124 0.5373269 
      
      
      
      
      
      
      
      
      
Table 4:  Partial list of correlation between 3’UTR methylation and gene 
expression by tissue type. 
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This prompted a closer look at how methylation of the 3’UTR relates to gene 
expression, particularly whether this is a passenger modification and its association 
with gene expression could be attributed to another variable, or whether levels of 
3’UTR methylation are the key differentiators of how highly genes are expressed. 
 
Subsection 4.2: Differences in expression between normal and cancer 
unexplained by promoter methylation or copy number variation. 
To examine whether other drivers of gene expression more suitably explained 
differences in gene expression, we focused on HOXC13 for several reasons, 
including a strong positive correlation (> 0.5 between 3’UTR methylation and gene 
expression in all 10 examined tissues), a comprehensive set of probes interrogating 
each region of the gene, and significantly higher expression in tumor tissues than in 
corresponding normal tissues (Fig55.). 
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Figure 55: Dotplot of log2 RNA-seq expression values across 10 TCGA tissue 
samples; black stars indicate normal tissue samples. The gene was overexpressed 
in tumors compared with in the corresponding normal samples. 
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 Furthermore, HOXC13 exhibits significantly elevated levels of methylation at the 
3’UTR (all p-values < 0.001) when comparing tumors to normal samples in bladder, 
breast, colorectal, head and neck, lung, and uterine tissue types, suggesting that 
3’UTR methylation may be a primary driver of this differential expression. To further 
investigate the nature of this variation, we examined common processes known to 
account for differential gene expression, primarily promoter methylation and copy 
number variation. First, we addressed possible allelic gain or loss using the TCGA 
copy number data for these tissue types (Fig56.). 
 
                
Figure 56: Copy number alterations in HOXC13 for the same samples. There is 
no evidence of copy number gain or loss in HOXC13. 
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 There was no significant HOXC13 gene amplification or deletion across all 10 
tumor types. Specifically, < 5% of cases had any reported copy number alterations in 
the HOXC13 gene region, making it unlikely that copy number is driving the observed 
variation in expression.  
 
We also considered whether the difference in HOXC13 expression between 
normal and tumor tissues could be due to divergent promoter methylation. Two tumor 
types, lung squamous and bladder cancer were selected as representative examples, 
as they demonstrated the greatest variation in gene expression between tumor and 
normal samples (Fig57.).  
Less than 10% of samples in the lowest quartile of gene expression have any 
evidence of methylation in the promoter region of HOXC13, strongly suggesting that 
differences in promoter methylation cannot account for the observed differences in 
expression. Next, we characterized the 3’UTR methylation pattern of high and low 
HOXC13 expressers and discovered that > 90% of samples in the highest quartile of 
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expression have methylated 3’UTRs, further implicating 3’UTR methylation as a 
potential driver of expression.  
 
 
Figure 57: Heatmaps representing the methylation patterns across HOXC13 in bladder and 
lung squamous cell carcinomas. The row color bar depicts the gene structure: purple, promoter 
region; light green, 5’UTR; dark green, first exon; grey, body; red, 3’UTR. The column color bar 
represents the top 25% gene expressers in pink and the bottom 25% expressers in black. 
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Subsection 4.3: Extent of 3’UTR methylation can predict overall survival. 
Considering the genome-wide changes in methylation patterning exhibited by 
tumors, and the clinically actionable nature of these modifications due to the 
reversible nature of DNA methylation(246), genome-wide differences in 3’UTR 
methylation between tumor and normal tissues in genes with a > 0.5 correlation 
coefficient between 3’UTR methylation and gene expression were examined. 
Because of observed divergence in 3’UTR methylation between tumor and normal 
tissues in certain genes, it was hypothesized that these genes might play roles in 
tumorigenesis and progression; therefore, we sought to determine whether these 
genes track with overall survival. Within five of the tumor types, including head and 
neck, lung adenocarcinoma, lung squamous, bladder, and kidney renal cell, we saw 
significant changes in survival associated with methylation at the 3'UTR (Table 5). 
 
 
Table 5:  The first row of the table represents the total number of differentially methylated 
genes that had significant separation in overall survival (p < 0.05). The second column 
represents the number of genes we would have expected to be significantly associated with 
survival on the basis of Poisson distribution if the genes had been chosen at random. The 
final row summarizes the total number of differentially methylated genes that were positively 
correlated with a 3’UTR > 0.5. 
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 Using kidney renal cell carcinoma (KIRC) as an example, of the 38 genes with 
differential 3’UTR methylation between normal and cancer, 22 showed significant 
separation in overall survival at a p-value of 0.05. For example, methylation at the 
3'UTR of the myosin 1G (MYO1G) gene in KIRC is highly correlated with gene 
expression, and patients with the lowest 20% methylation levels have significantly 
better survival (p<0.001) than those with the highest 20% (Fig58.). 
 
 
Figure 58: Differences in patient overall survival on the basis of methylation status 
using an example gene, MYO1G, in the context of kidney renal clear cell carcinoma. 
The red and blue points in the dotplot (B, left panel) distinguish the samples with the 
highest and lowest 20% of methylation, respectively. (right panel) The same samples 
were used to evaluate the difference in overall survival between these groups. 
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This proportion is significantly greater than the 2 genes expected to be 
associated with survival had 38 genes been selected at random. In summary, extent 
of 3’UTR methylation in a significant number of genes is associated with overall 
survival in 5 of 10 tumor types examined, suggesting that 3’UTR methylation may be 
a functionally relevant modification in cancer pathogenesis.  
 
Subsection 4.4: Genes in which expression is uniquely correlated with 3’UTR 
DNA methylation are enriched for those involved in T cell activation.  
Because the majority of genes from this analysis exhibit a positive correlation 
between gene body methylation and expression, those genes in which 3’UTR 
methylation had a > 0.5 correlation coefficient with gene expression and < 0.5 in the 
gene body were selected for further analysis. The most exemplary gene exhibiting 
this phenomenon, ITK, contains robust positive correlation in the 3’UTR, but negative 
correlation in the gene body (Fig59.).  
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Figure 59: A representative plot of the relationship between methylation and gene 
expression on the ITK gene body. The top box represents the gene layout, with the blue 
portion highlighting the 3’UTR. In the “correlations” box, each line represents a tissue type. 
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Filtering using these criteria yielded a list of 156 genes (Table 6).  
 
 
Table 6:  List of genes that exhibit a correlation coefficient of > 0.5 between gene 
expression and 3’UTR methylation, but a correlation coefficient of < 0.5 between gene 
expression and gene body methylation, in at least two tissue types. 
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These genes were then subjected to a pathway analysis, which revealed an 
enrichment of genes involved in regulating various aspects of T cell activation (Table 
7).  
 
 
 
Table 7:   A NetWalker analysis of the 156 genes shows the correlation between 
gene expression and 3’UTR methylation of > 0.5 and gene body methylation of < 
0.5. T cell activation and antigen presentation were the most overrepresented 
pathways. 
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This includes genes involved in T cell receptor signaling (ITK, VAV1) and T cell 
exhaustion (HAVCR2), as well as antigen presentation, particularly regarding the 
MHC class II complex (HLA-DQA1, HLA-DOA). These genes were then subject to a 
network analysis using NetWalker, which uncovered a single interconnected node of 
23 genes, of which 7 genes are involved in T cell activation (Fig60.). 
 
 
Figure 60: A single network node with more than 1 
interaction was identified using a Netwalker analysis. The 
genes in the red box represent genes that are canonically 
expressed in T cells and are known to be integral to T cell 
activation. 
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The protein products of three genes (ITK, HAVCR2, VAV1) interact with each other, 
and are primarily expressed in T cells. Furthermore, these genes contain a positive 
correlation between gene expression and 3’UTR methylation of > 0.5 and gene body 
methylation of < 0.5 in 2 or more tissue types, as is observed with VAV1 (Fig61.). 
               
Figure 61: A representative plot of the relationship between methylation and gene 
expression on the VAV1 gene body. The top box represents the gene layout, with 
the blue portion highlighting the 3’UTR. In the “correlations” box, each line 
represents a tissue type. 
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Additionally, the immune checkpoint gene HAVCR2 also exhibits this phenomenon, 
and interacts with both VAV1 and ITK (Fig62.). 
 
 
    
Figure 62: A representative plot of the relationship between methylation and gene 
expression on the HAVCR2 gene body. The top box represents the gene layout, 
with the blue portion highlighting the 3’UTR. In the “correlations” box, each line 
represents a tissue type. 
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 Because the samples analyzed are tumor tissues that contain immune cells, 
we wondered whether methylation and expression differences in T cell-related genes 
were occurring within tumor cells or within T cells present in the tumor samples.  
 
To determine whether the 3’UTR methylation phenomenon should be 
investigated within tumor cells, or within T cells, the expression of the three T cell-
specific genes listed above (ITK, VAV1, and HAVCR2) were plotted against estimated 
levels of T cells using previously established methodology for ascertaining T cell 
count in TCGA samples (244). For each of these three genes, a highly significant 
association was discovered between expression and T cell count was observed for 
ITK (Fig63.). 
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Figure 63: The expression of ITK (x-axis) was compared to the estimated number of T 
cells (y-axis) in each TCGA sample, revealing a robust correlation. 
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VAV1 expression also showed a very strong correlation with T cell count (Fig64.). 
 
 
 
 
 
 
 
 
Figure 64: The expression of VAV1 (x-axis) was compared to the estimated number 
of T cells (y-axis) in each TCGA sample, revealing a robust correlation. 
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Additionally, HAVCR2 expression was robustly associated with T cell count (Fig65.). 
 
 
 
 
 
  
 
Figure 65: The expression of HAVCR2 (x-axis) was compared to the estimated 
number of T cells (y-axis) in each TCGA sample, revealing a robust correlation. 
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These data support the conclusion that for the analyzed genes, 3’UTR methylation 
being connected to gene expression is occurring within T cells. Based upon these 
findings, the relationship between 3’UTR methylation and gene expression of these 
genes was examined in T cells. 
 
Subsection 4.5: Increased DNA methylation of Havcr2 specific to the 3’UTR 
occurs in conjunction with upregulated gene expression after T cell activation. 
T cells are known to dynamically modulate DNA methylation when changing 
activation states (247), and a specific epigenetic profile is essential for proper 
function. Therefore, changes to 3’UTR methylation and gene expression of Itk, Vav1, 
and Havcr2 were examined after isolating T cells from c57Bl/6 mice and activating 
the T cells ex vivo. 72 hours after stimulation, expression of Vav1 was unchanged, 
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and Itk expression decreased slightly; however, Havcr2 expression increased by 
nearly 50-fold (Fig66.). 
 
 
Figure 66: T cells isolated from C57Bl/6 mice and activated ex vivo had no significant 
differences in Itk or Vav1 gene expression, whereas the gene expression of Havcr2 was 
substantially increased. Likewise, 3’UTR methylation of Itk and Vav1 exhibited minimal 
differences after T cell activation, whereas Havcr2 3’UTR methylation increased by 2.5-
fold. 
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Next, two CpG sites within the 3’UTR for each gene were examined for changes to 
DNA methylation. Similar to gene expression, Vav1 3’UTR methylation did not differ 
between naïve and activated T cells, whereas Itk 3’UTR methylation decreased 
slightly; however, Havcr2 3’UTR methylation increased substantially, approximately 
2.5-fold higher at both sites in activated T cells relative to naïve (Fig67.). 
            
 
Figure 67: Methylation of the Havcr2 promoter region in naïve T 
cells was low, and activated T cells displayed a significant decrease; 
however, this promoter lacks a CpG island and is not likely to 
regulate Havcr2 gene expression. Methylation of the adjacent exon 
increases slightly, and methylation of the intron immediately 
adjacent to the 3’UTR shows no significant changes. 
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To determine whether this increase in Havcr2 expression was due to changes 
in promoter methylation, as is the case for many genes switched on after T cell 
activation, methylation of the promoter region was assayed. While a significant 
decrease was observed in methylation of the promoter region after activation, very 
low promoter methylation was observed in the naïve state, and the Havcr2 promoter 
lacks a CpG island, indicating that this modification is likely not the major regulator of 
gene expression. Next, methylation of the exon and intron immediately adjacent to 
the 3’UTR of Havcr2 was examined. Methylation of the intron did not change upon 
activation, and methylation of the adjacent exon showed a slight increase in 
methylation, however, not nearly as substantial as that of the 3’UTR (Fig68.). These 
data demonstrate the exquisite specificity with which robust increases in methylation 
are targeted to the 3’UTR. 
 
 
 
Figure 68: Schematic of the Havcr2 gene, with the location of the interrogated sites in 
each discrete region of the gene highlighted. 
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Subsection 4.6: Treatment with decitabine, or knockout of Dnmt3a results in 
reduced Havcr2 gene expression. 
To investigate whether increases in DNA methylation were necessary for the 
increase in Havcr2 gene expression, T cells were activated ex vivo, then treated with 
the DNMT inhibitor decitabine, or DMSO vehicle as a control. After 72 hours, the 
activated T cells treated with decitabine showed a 4-fold decrease in Havcr2 gene 
expression relative to the DMSO-treated T cells, indicating that DNA methylation is 
upstream of upregulated Havcr2 gene expression after T cell activation (Fig69.).  
              
Figure 69: Havcr2 gene expression after ex vivo activation of T cells and subsequent 
treatment with the demethylating agent decitabine. Treatment with decitabine causes 
a four-fold decrease in Havcr2 expression. 
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These data highlight de novo DNA methylation as an important component of 
modulating gene expression after activation, as observed in previous studies (1). As 
further evidence of this observation, the gene expression profile of exhausted T cells 
from a Dnmt3a knockout mouse were examined using gene array and genome-wide 
bisulfite sequencing data obtained from Ghoneim et al(1). From this gene array, 
Havcr2 was fifth-most downregulated gene in exhausted CD8 T cells lacking Dnmt3a 
relative to wild-type (Fig70.), supporting the conclusion that de novo methylation of 
Havcr2 3’UTR results in increased gene expression. 
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Figure 70: Heat map of the top genes whose expression was most altered in naïve 
or exhausted T cells after Dnmt3a knockout. Havcr2 expression was the 5th-most 
decreased in Dnmt3a knockout exhausted T cells(1). 
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The difference in Havcr2 expression after Dnmt3a knockout in naïve and exhausted 
T cells was then quantified, revealing a significant decrease in Havcr2 expression 
after Dnmt3a knockout in exhausted, but not naïve, T cells (Fig71.). 
 
      
Figure 71: Quantitative expression data for Havcr2 expression in naïve or 
exhausted T cells after Dnmt3a knockout. 
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Next, using the bisulfite array data generated from this study, the gene body 
methylation of Havcr2 was compared between wild-type and Dnmt3a knockout CD8+ 
T cells. This revealed that a substantial decrease in Havcr2 methylation occurred 
within the 3’UTR, whereas most sites within the rest of the gene body remained 
relatively unchanged (Fig72.), independently confirming the site specificity of Havcr2 
methylation. 
 
 
Figure 72: Visualization of bisulfite sequencing array data that shows extent of methylation 
of Havcr2 gene. The top portion is the entire gene, and the bottom portion is the 3’UTR. 
The 3’UTR shows the most substantial change in methylation after Dnmt3a knockout in 
exhausted T cells. 
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Section 5: Discussion 
Subsection 5.1: The implications of CARD11 gene body methylation, and role 
in KIRC and LUAD pathogenesis 
The results of this analysis have revealed two important findings: 1) aberrant 
expression of CARD11 in renal cell carcinoma and lung adenocarcinoma can 
promote cancer pathogenesis through changes to mTOR signaling and autophagy, 
and 2) CARD11 gene body methylation results in increased expression. 
This study expands our understanding of the creative means by which tumor 
cells activate genes otherwise unexpressed in their tissue of origin, and to co-opt 
downstream signaling pathways that serve to propel tumor malignancy forward. In 
the case of CARD11, this lymphocyte-specific gene canonically links the T- and B-
cell receptors to the NF-kB pathway, thereby mediating lymphocyte activation upon 
antigen stimulation. Based upon this knowledge, CARD11 overexpression in the 
context of renal cell carcinoma and lung adenocarcinoma was hypothesized to 
increase NF-kB activation even in the absence of antigen receptors. Surprisingly, 
knockdown of CARD11 did not affect the NF-kB pathway, instead conveying its 
effects primarily through the mTOR axis. CARD11 has been shown previously to be 
involved in proper mTOR activation in T cells, but this is the first time this 
phenomenon has been observed in cells of epithelial origin.  
While localized renal cell carcinoma can be eliminated through procedures 
such as resection of the kidney or heat/cold ablation therapy, approximately one third 
of patients with clear cell renal cell carcinoma develop metastasis(248). Stage IV 
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renal cell carcinoma has a survival rate of only 10%, and is highly resistant to 
chemotherapy(249), necessitating more efficacious therapeutic approaches. The 
mTOR pathway, which is an important component of damage response in the kidney, 
is a key mediator of cancer pathogenesis in renal cell carcinoma(250). It is 
hypothesized that this is due to the reliance of renal cancer on HIF-1α and HIF-2α; 
these two proteins depend on mTOR activation for efficient translation(251). Based 
on this observation, small molecule inhibitors of mTOR such as Temsirolimus and 
Everolimus have been employed to treat advanced stage metastatic renal cell 
carcinoma, with patients showing longer overall survival(252) and progression-free 
survival(253) from these drugs, respectively. However, resistance to these therapies 
emerges over time, primarily through compensatory activation of the MAPK pathway. 
Current clinical trials combining mTOR inhibitors with MAPK inhibitors have been 
limited by toxicity(254); therefore, new, less toxic approaches in targeting the mTOR 
pathway are needed. Because CARD11 is not expressed by normal kidney cells, this 
offers an opportunity to suppress mTOR activation while not impacting the kidney. 
Moreover, targeting CARD11 gene body methylation may provide a highly selective 
means by which CARD11 expression, and downstream mTOR signaling, may be 
suppressed. However, the prevalence of CARD11 gene body methylation in T and B 
cells, and how demethylation impacts the function of these cells, requires to be 
investigated before targeting this region with site-specific demethylation can achieve 
clinical adoption. 
In addition to further supporting the finding that tumor cells can utilize non-
canonical pathways, this analysis also reveals how tumor cells employ non-canonical 
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mechanisms to induce aberrant expression of genes that are otherwise silenced by 
their tissue of origin. Previous studies have uncovered various means by which this 
process is undertaken. These include promoter demethylation, upregulation of 
transcription factors, changes to chromatin architecture, and downregulation of 
microRNAs, among many others. Here, we have provided further evidence that gene 
body DNA methylation is an alternative mechanism by which tumor cells can alter 
their transcriptional profile during tumorigenesis and tumor progression. This serves 
to reiterate the importance of examining gene body DNA methylation as a means of 
fully understanding transcriptional regulation, and that targeting this type of epigenetic 
modification is a newly emerging route to modulate aberrant gene expression.  
The past 20 years has seen gene regulation by RNAs becoming more 
prominent and expansive. The most famous, miRNAs, have been shown to entire 
axes of cellular function. Lnc-RNAs can induce changes to chromatin, recruit 
transcription factors, or bind mRNAs. Importantly, they are also known to modulate 
DNA methylation by associating with DNMT1, DNMT3A & B, or GADD45A/TDG, 
among others. Because antisense RNAs contain part or all of their sequence that is 
reverse complement to the sense strand, this allows for remarkable specificity in 
localizing proteins, such as methylation enzymes, to select loci. Furthermore, over 
30% of the genome produces some form of antisense transcript. Despite these 
unique properties, the vast majority of the antisense RNAome has never been 
studied. A certain portion of these antisense RNAs may not serve a function at all, 
and can be discarded as transcriptional noise, but this study highlights the need to 
catalog the thousands of antisense RNAs that exist, and how they are involved in 
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normal and abnormal cellular processes. As systemic siRNA therapies become more 
accepted in the clinic, antisense RNAs make promising candidates for a new frontier 
of targets in cancer. However, in this study, we have determined that the CARD11-
NAT does not regulate CARD11. Despite this, we have concluded that these two 
transcripts are co-regulated by the gene body CpG island. Considering CARD11-NAT 
is spliced, and is highly overexpressed in multiple cancer types, it could be 
functionally relevant both for normal cellular processes as well as in cancer. On the 
other hand, its increased expression in cancer may simply be a byproduct of 
increased CARD11 expression. The role this NAT plays in cellular biology must be 
further explored. 
What prompts the increase in CARD11 DNA methylation during tumorigenesis 
and tumor development still remains to be understood. As mentioned, tumor cells 
exhibit global hypomethylation, but hypermethylation in regions such as the 
promoters of tumor suppressor genes. What specific factors guide DNA methylation 
enzymes to establish this site-specific hypermethylation, and whether there is a 
mechanistic overlap between gene body hypermethylation and promoter methylation, 
necessitate investigation.  
In conclusion, these data have revealed the role that the lymphocyte-specific 
gene CARD11 is upregulated in certain epithelial cancers, and overexpression is 
strongly associated with decreased patient overall survival in kidney renal cell 
carcinoma. CARD11 can activate the mTOR pathway in the context of epithelial 
cancer, while not impacting the canonical NF-kB pathway. The expression of 
CARD11 is regulated by methylation of the CpG island within the gene body, which 
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increases expression. Therefore, this study emphasizes the importance of 
considering how methylation can increase expression of oncogenes, and provides 
novel insight into how oncogenes are activated during tumorigenesis and tumor 
progression. 
 
Subsection 5.2: The relationship between 3’UTR methylation and expression, 
and the implications of 3’UTR methylation in T cell activation genes and beyond 
Ascertaining the functional and clinical effects of site-specific DNA methylation 
remains an important step in unraveling the many layers of epigenetic regulation. 
Here, we found that the 3’UTR is a functionally distinct site for epigenetic modification. 
DNA methylation of the gene body is known to be associated with increased gene 
expression, but by separately examining the 3’UTR across both normal and tumor 
tissue samples, we revealed an enrichment of DNA methylation sites in this region 
that are uniquely correlated with increased gene expression. Moreover, we identified 
several genes that exhibited divergent gene expression between normal and tumor 
tissues; they lacked significant alterations in copy number or promoter methylation 
that would explain the differences in expression independently of changes in 3’UTR 
methylation. In 5 of the 10 tumor types examined, 3’UTR methylation was associated 
with patient overall survival in a significant number of genes.  
Interestingly, by separating out the 3’UTR as a distinct functional region for the 
first time, an unexpected link between DNA methylation of this region and T cell 
regulation was observed. For certain genes in this category, particularly those related 
to T cell receptor activation (Itk and Vav1), the extent of 3’UTR DNA methylation was 
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correlated with both the presence of T cells in a tumor and with patients’ overall 
survival. For the progressively important immune checkpoint gene Havcr2, DNA 
methylation of the 3’UTR may serve as a means by which T cell exhaustion occurs. 
TIM-3-expressing T cells exhibit a severely exhausted phenotype (255, 256), and this 
protein is frequently found to be expressed in tumor-infiltrating lymphocytes (257). In 
addition, the expression of TIM-3 promotes resistance to PD-1/PD-L1 blockade (258), 
and de-methylating agents, in combination with PD-1/PD-L1 blockade, exhibit greater 
sensitivity (1). DNA methylation inhibition and the subsequent sustained or increased 
expression of Havcr2 may be an underlying reason for this observation.  
These data suggest two new avenues of exploration that will broaden our 
understanding of this epigenetic modification. The first is ascertaining how 3’UTR 
methylation influences gene expression. It is well established that DNA methylation 
affects the binding of regulatory proteins (41). In the case of proteins with methylation-
binding domains, DNA methylation can increase binding (259, 260). On the other 
hand, DNA methylation can inhibit protein binding or mask sequence recognition, as 
is the case for many transcription factors (30). Another potential explanation for the 
effect of the 3’UTR on gene expression may be differential alternative splicing and 
alternative polyadenylation. Gene body methylation has already been shown to affect 
exon inclusion (261); alternative polyadenylation has not been linked with DNA 
methylation, but if different lengths of the 3’UTR are dependent on methylation, 
transcripts with shorter 3’UTRs would have greater mRNA stability and thereby more 
gene expression (262). However, gene body methylation has also been observed as 
142 
 
a consequence of higher gene expression, rather than as a cause (263); therefore, 
3’UTR methylation may occur downstream of higher gene expression.  
The second question arises in regard to how 3’UTR methylation is regulated. 
De novo DNA methylation is deposited by the DNMT3 enzymes (264), and de novo 
demethylation is handled by the TET family of enzymes; therefore, these are likely to 
play a role in producing the differential methylation observed in tumor and normal 
tissues and in activated versus naïve T cells. Indeed, given the substantial decrease 
in Havcr2 gene expression after Dnmt3a knockout, this enzyme in particular seems 
to be involved. However, the co-factors that position these enzymes in a tightly 
controlled spatial and temporal context are currently unknown.  
These data have multiple implications. First, these genes may play a 
previously unidentified role in cancer pathogenesis. Second, 3’UTR methylation of 
these genes may serve as a biomarker for disease presence and progression. Finally, 
demethylating this region may serve as a target for cancer therapy; how 
demethylating agents affect the 3’UTR should be taken into account when evaluating 
the mechanism and efficacy of these therapies.  
Taken together, our findings indicate that the 3’UTR is a region of epigenetic 
importance. These data raise the possibility of a novel component of epigenetic 
regulation that operates during T cell development and activation, as well as other 
cellular processes. Furthermore, they shed light on a potential novel mechanism by 
which T cells upregulate immune checkpoint mediators. In addition, the disrupted 
patterns of 3’UTR methylation observed in cancer suggest that alterations in 3’UTR 
methylation play a role in tumorigenesis and tumor progression. Coupled with the 
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Cas9-Tet1 technology developed here and elsewhere, the capacity to specifically 
modulate the epigenome has finally come into reach. Given this advancement, 
decoding the functional implications of site-specific modifications to the DNA and 
histones has taken on even greater importance.  The findings reported here broaden 
our understanding of the effect of DNA methylation on cellular processes, and most 
importantly, they highlight novel components of cancer pathogenesis, opening new 
avenues for clinical therapy. Future research should focus on which modification sites 
are most critical for cancer pathogenesis, as well as optimizing both the efficiency 
and delivery of constructs that can target these sites. Achieving these aims hold the 
potential to grant exquisite control over the epigenome. 
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